CURRICULUM VITAE

Yu Shyr, Ph.D.

PRESENT POSITION **June 1, 2014**

Harold L. Moses Chair in Cancer Research
Vanderbilt University School of Medicine

Director
Center for Quantitative Sciences
Vanderbilt University School of Medicine

Director
Vanderbilt Technologies for Advanced Genomics Analysis and Research Design
Vanderbilt University School of Medicine

Associate Director for Quantitative Sciences Integration
Vanderbilt-Ingram Cancer Center
Vanderbilt University School of Medicine

Professor
Department of Biostatistics
Vanderbilt University School of Medicine

Department of Cancer Biology
Vanderbilt University School of Medicine

Department of Biomedical Informatics
Vanderbilt University School of Medicine

Department of Health Policy
Vanderbilt University School of Medicine

Address: 571 Preston Research Building
Center for Quantitative Sciences
Vanderbilt University School of Medicine
Nashville, TN 37232-6848

Telephone: (615) 936-2572

Fax: (615) 936-2602

E-mail: yu.shyr@vanderbilt.edu

EDUCATION

1981 – 1985	*B.B.,* Statistics Tamkang University (Taiwan)
1987 – 1989	*M.S.,* Statistics Michigan State University
1989 – 1994	*Ph.D.,* Biostatistics University of Michigan, Ann Arbor Dissertation: Some Aspects of Canonical Correlation Analysis

EXPERIENCE

1988 – 1989	***Graduate Student Teaching Assistant (GSTA)*** Department of Statistics Michigan State University
1989 – 1994	***Graduate Student Research Assistant (GSRA)*** Department of Biostatistics University of Michigan
1990	***Research Associate*** Institute of Gerontology University of Michigan
1991 – 1992	***Research Associate*** Department of Periodontics/Prevention/Geriatrics School of Dentistry University of Michigan
1993 – 1994	***Adjunct Lecturer*** Department of Biostatistics University of Michigan
1994 – 1998	***Chief Biostatistician*** Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine
1994 – 1999	***Assistant Professor of Biostatistics*** Department of Preventive Medicine Vanderbilt University School of Medicine
1997 – 1998	***Consultant*** Lexicon Genetics, Incorporated
1997 – 2000	***Consultant*** Applied Medical Research, Incorporated
1998 – present	***Director, Biostatistics Shared Resource*** Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine
1999 – 2002	***Associate Professor of Biostatistics*** Department of Preventive Medicine Vanderbilt University School of Medicine
2000	***Acting Director, Division of Biostatistics*** Department of Preventive Medicine Vanderbilt University School of Medicine
2001 – present	***Faculty*** Center for Technology-Guided Therapy Vanderbilt University School of Engineering Vanderbilt University School of Medicine
2001 – 2012	***Director, Biostatistics Core*** Lung Cancer SPORE Vanderbilt University School of Medicine
2001 – present	***Co-Director, Epidemiology/Biostatistics Core*** Meharry/Vanderbilt Cancer Center Alliance Grant Vanderbilt University School of Medicine Meharry Medical College
2002 – present	***Director, Biostatistics and Bioinformatics Core*** GI Cancer SPORE

	Vanderbilt University School of Medicine
2003 – present	***Director, Biostatistics Core*** Breast Cancer SPORE Vanderbilt University School of Medicine
2003 – 2013	***Professor of Biostatistics*** Department of Preventive Medicine Vanderbilt University School of Medicine
2003 – present	***Professor*** Department of Biostatistics Vanderbilt University School of Medicine
2003 – 2013	***Ingram Professor of Cancer Research*** Vanderbilt University School of Medicine
2004 – 2006	***Consultant*** CooperSurgical, Incorporated
2005 – 2012	***Adjunct Professor*** School of Medicine Tokai University, Japan
2006 – present	***Chief*** Division of Cancer Biostatistics Department of Biostatistics Vanderbilt University School of Medicine
2006 – present	***Invited Professorship*** Shanghai Center for Bioinformatics Technology, China
2006 – present	***Affiliate Professor*** Department of Statistics National Chen Kung University, Taiwan
2007 – 2011	***Director*** Cancer Biostatistics Center Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine
2007 – 2009	***Consultant*** Westat, Incorporated Rockville, MD
2009 – present	***Associate Director for Quantitative Sciences Integration*** Vanderbilt-Ingram Cancer Center Vanderbilt University School of Medicine
2009 – present	***Director*** Statistical Center Sentinel Node Oncology Foundation (SNOF)
2010 – present	***Consultant*** GlaxoSmithKline Oncology
2011 – present	***Visiting Chair Professor*** Department of Bioinformatics and Biostatistics Shanghai Jiao Tong Univeristy, China
2011 – present	***Director*** Center for Quantitative Sciences Vanderbilt University School of Medicine
2011 – present	***Professor*** Department of Cancer Biology

	Vanderbilt University School of Medicine
2011 – present	***Professor*** Department of Biomedical Informatics Vanderbilt University School of Medicine
2012 – present	***Director*** Vanderbilt Technologies for Advanced Genomics Analysis and Research Design Vanderbilt University School of Medicine
2013 – present	***Harold L. Moses Chair in Cancer Research*** Vanderbilt University School of Medicine
2013 – present	***Professor*** Department of Health Policy Vanderbilt University School of Medicine

HONORS

1. American Statistical Association Chapter Service Recognition Award, 2000.
2. Invited Keynote Speaker of Taiwan Biotechnology Symposiums, 2000.
3. Chair Professor of Statistics at Tamkang University, 2000.
4. Vanderbilt University School of Medicine Master of Science in Clinical Investigation Program Excellence in Teaching Award, 2002, 2003, 2004.
5. Endowed Professorship: Ingram Professor of Cancer Research, 2003.
6. Invited Keynote Speaker of 2003 Meeting of the Louisiana Chapter of the American Statistical Association.
7. Invited Keynote Speaker of 2008 Biostatistics and Bioinformatics Workshop in High-Dimensional Data Analysis, Taipei, Taiwan.
8. Distinguished Alumni Award of Department of Statistics, Tamkang University, 2008.
9. American Statistical Association, Fellow, 2010
10. Invited Keynote Speaker, Japan Symposium on Innovation in Medical Research and Ethical Challenges, Tokyo, Japan, 2010.
11. Highest Rated Lecture, AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2010, 2012, 2013.
12. Invited Keynote Speaker, International Conference on Applied Statistics, Taipei, Taiwan, 2011.
13. Scientific Review Committee Award for Exceptional Service and Dedication, Vanderbilt-Ingram Cancer Center, 2011.
14. Jacek Hawiger Award for Teaching Graduate Students and Postdoctoral Fellows in the Classroom, Lecture, or Small Group Setting, Vanderbilt University, 2012.
15. Academy for Excellence in Teaching: Member, Vanderbilt University, 2013.
16. Harold L. Moses Chair in Cancer Research, 2013.

PROFESSIONAL SOCIETIES

1. American Statistical Association
2. American Association for Cancer Research

3. American Society for Clinical Oncology
4. International Biometrics Society
5. Institute of Mathematical Statistics
6. Society for Clinical Trials
7. Society for Epidemiologic Research
8. International Chinese Statistical Association
9. International Association for the Study of Lung Cancer

TEACHING, WORKSHOPS, AND SEMINARS

1 At Vanderbilt

- "Statistical Issues and Analyses of a Study of the Use of Condoms in Urban, Low-Income, Minority Youth," Department of Preventive Medicine Seminar, 1994.
- "Statistics and Epidemiology" in Preventive Medicine Course, 1995.
- "Statistical Power and Sample Size Calculations," Cancer Center Seminar, 1995.
- "The Analysis of Lifetime Data," Cancer Center Seminar, 1995.
- "Analysis of Epidemiologic and Clinical Data," Cancer Center Seminar, 1995.
- "Fundamentals of Clinical Trials," Cancer Center Seminar, 1995.
- "Statistics and Epidemiology" in Preventive Medicine Course, 1996.
- "Longitudinal Analysis of Sinusoidity of Time-Qualified Data," Preventive Medicine Seminar, 1996.
- "Clinical Trials," (MPH-5145504): Taught, 1996.
- Cancer Center Biostatistics Workshop, 1996.
- "Statistics and Epidemiology" in Preventive Medicine Course, 1997.
- "Using and Understanding Medical Statistics," in Department of Surgery Resident Training, 1997.
- "Understanding, Applying, and Not Misusing the Survival Analysis Techniques in Clinical Trials," Medical Oncology Division Seminar, 1997.
- "Statistical Methods for the Analysis of Biomedical Data," Nephrology Clinical Journal Club, 1997.
- "Statistical Issues and Analyses of a Study of the Risk Factors for Hospitalization in Well-Dialyzed Chronic Hemodialysis Patients," Department of Preventive Medicine Research Conference, 1997.
- Cancer Center Biostatistics Workshop, 1997.
- "Clinical Trials" in Preventive Medicine Course, 1998.
- "Statistics and Epidemiology" in Preventive Medicine Course, 1998.
- "Clinical Trials" (MPH-5145504): Taught, 1998.
- "Sample Size Determination for the Two-stage Design of a Phase II Cancer Clinical Trial with Correlated Unbalanced Binary Endpoints," Department of Preventive Medicine Research Conference, 1998.
- Cancer Center Biostatistics Workshop, 1998.
- "Statistics and Epidemiology" in Preventive Medicine Course, 1999.

- "Clinical Trials" in Preventive Medicine Course, 1999.
- "Statistics in Medical Literature" in Preventive Medicine Course, 1999.
- Vanderbilt-Ingram Cancer Center Biostatistics Workshop, 2000.
- "Dose Modification in a Phase II Clinical Trial with Toxicity Endpoints: Statistical Strategies for Analysis," Department of Preventive Medicine Seminar, 2000.
- "Clinical Trials" in Preventive Medicine Course, 2000.
- "Statistics in Medical Literature," in Preventive Medicine Course, 2000.
- "Statistics and Epidemiology," in Preventive Medicine Course, 2000.
- "Statistical Issues in Clinical Research," in Department of Surgery Resident Training, 2000.
- "Clinical Trials" (MPH-5145504): Taught, 2000.
- "Statistical Cluster Analysis for Gene-Expression Profiles," in Bioinformatics Gene Expression/Proteomics Analysis Seminar, 2001.
- "Clinical Trials," in Preventive Medicine Course, 2001.
- "An Introduction to Cluster Analysis," in Statistical Genomics: Making Sense of all the Data Workshop, 2001.
- "Statistical Class-prediction Model," in Vanderbilt-Ingram Cancer Center Seminar, 2001.
- "Statistical Methods for Health Sciences," in Nephrology Clinical Conference, 2001.
- "Fundamentals of Clinical Trials," in Nephrology Clinical Conference, 2001.
- "Statistical Issues in Data Safety and Monitoring Committee," in General Clinical Research Center (GCRC), 2001.
- Vanderbilt-Ingram Cancer Center Biostatistics Workshop, 2001.
- "Clinical Trials" (MPH-5145504): Taught, 2001.
- "Clinical Trials," in Preventive Medicine Course, 2002.
- "Cluster Analysis," in Biomedical Informatics Graduate Course, 2002.
- "Analysis of RNA Expression Patterns in Human Lung Cancer Using Flexible Compound Covariate Method," Biomedical Informatics Seminar, 2002.
- "Applying Cluster Analysis in Proteomics Research," in Vanderbilt Proteomics Conference Workshop, 2002.
- "Design, Analysis and Interpretation of Microarray Data," in Vanderbilt Clinical Pharmacology Grand Rounds, 2002.
- "Statistical Methods for Genomic/Proteomic Pattern studies," in BMS Biomedical Informatics Course, 2002.
- "Clinical Trials" (MPH/MSCI-5145504): Taught, 2002.
- "Clinical Trials" in Preventive Medicine Course, 2003.
- "Statistical Methods for the Analysis of Microarray Data," in Nephrology Clinical Conference, 2003.
- "Clinical Trials" (MPH/MSCI-5145504): Taught, 2003.
- "Clinical Trials" in Preventive Medicine Course, 2004.
- "Clinical Trials" (MPH/MSCI-5145504): Taught, 2004.
- "Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays" in Meharry Medical College/Vanderbilt-Ingram Cancer Center 5th Annual Retreat & Mini Symposium, 2004.

- "Weighted Flexible Compound Covariate Method for Microarray and MALDI-TOF-MS Data Analysis," in Department of Biostatistics Seminar, 2004.
- “On Mass Spectrometry Data Preprocessing Using Mathematical Tools and Statistical Techniques,” in Department of Biostatistics Seminar, 2004.
- "Data and Safety Monitoring: A Consumer's Guide," in Clinical Pharmacology Grand Rounds, 2005.
- “Clinical Trials” in Preventive Medicine Course, 2005.
- "A Software Package for MALDI-TOF / Microarray Data Analysis," in Cancer Proteomics & Genomics Program Seminar, Vanderbilt-Ingram Cancer Center, 2005.
- "Clinical Trials" (MPH/MSCI-5145504): Taught, 2005.
- “Statistical Analysis for High Dimensional Data,” in IGP Program: Taught, 2005.
- “On Actuarial Models and Survival Analysis for Cancer Patients,” in Math Club Seminar, 2005.
- “Recent Development of Mass Spectrometry Data Processing Using Mathematical Tools and Statistical Techniques,” in VICC and UABCC Spring 2005 Inter-SPORE Biostatistics/Bioinformatics Workshop, 2005.
- “A Soft ware Package for MALDI-TOF MS Data Preprocessing and Statistical Analysis,” in Mass Spectrometry Research Center Seminar, 2005.
- “On Mass Spectrometry Data Preprocessing in Cancer Study,” in Biomath Study Group Seminar, 2005.
- “Clinical Trials” in Preventive Medicine Course, 2006.
- “Some Statistical Aspects of Oncology Phase II Trials,” in Vanderbilt Department of Medicine Seminar, 2006.
- “Clinical Trial Design,” in GCRC research skills workshop, 2006.
- “Interim Analysis in Clinical Trials,” in GCRC research skills workshop, 2006.
- “Randomization in Clinical Trials,” in GCRC research skills workshop, 2006.
- “Clinical Trials” (MPH/MSCI-5145504): Taught, 2006.
- “How to Consult Efficiently with Investigators – A Case Study of Clinical Trials,” in Department of Biostatistics Staff Biostatistician Workshop, 2007.
- “Novel Statistical Methods for Omics Research,” in Lung Cancer Program Retreat, 2007.
- “Clinical Trials” (MPH/MSCI-5145504): Taught, 2007.
- “Biomathematics & Bioinformatics in Tumor Micro-Environment Research,” in Vanderbilt University Tumor Micro-Environment Network (VUTMEN) Seminar, 2007.
- “Statistical Issues in Clinical Trials,” in Division of Hematology/Oncology Seminar, 2007.
- “Clinical Trials,” in Eskind Biomedical Library Training Program: Taught, 2008.
- “Clinical Trials,” in Preventive Medicine Course, 2008.
- “Science of Doing Science – Biostatistics,” in Cancer Biostatistics Workshop, 2008.
- “Bioinformatics & Biostatistics in Clinical Proteomics Research,” in MSCI Clinical Proteomics Course, 2008.
- “Clinical Trials” (MPH/MSCI-5145504): Taught, 2008.
- Vanderbilt-Ingram Cancer Center Biostatistics Workshop, 2009.
- “Clinical Trial Design,” in CRC research skills workshop, 2009.
- “Randomized Controlled Trials,” in Medical School Preventive Medicine course, 2009.
- “Clinical Trials" (MPH-5145504): Taught, 2009.

- "Clinical Trial Design," in CRC research skills workshop, 2010.
- "Clinical Trials" (MSCI-504401): Taught, 2010.
- "Biostatistics for Regulators and Politicians: Why Statisticians Need to Be Activists?": in Department of Biostatistics Seminar, 2010.
- "Clinical Trials" (MPH-5145504): Taught, 2010.
- "Advanced Data Analysis with Case Studies," in Eskind Biomedical Library Training Program: Taught, 2011.
- "Challenges and Opportunites for Biostatisticians: Why Biostatisticians Need to Be Activists!" in Department of Biostatistics MS Staff Retreat, 2011.
- "Randomized Controlled Trials," in Patient, Physician, and Society-II: Taught, 2011.
- "Clinical Trials" (MSCI-504401): Taught, 2011.
- "Randomized Clinical Trials," in Internal Medicine resident course: Taught, 2012.
- "Clinical Trials," in IGP Program: Taught, 2012.
- "Advanced Statistical Bioinformatics for Omics Research," in Eskind Biomedical Library Training Program: Taught, 2012.
- "Randomized Controlled Trials," in Patient, Physician, and Society: Taught, 2012.
- "Biostatistics I" (MPH-5445502): Taught, 2012.
- "Clinical Trials" (MSCI-504401): Taught, 2012.
- "Clinical Trials," in IGP Program: Taught, 2013.
- "Meta-Analysis," in Eskind Biomedical Library Training Program: Taught, 2013.
- "Biostatistics I" (MPH-5445502): Taught, 2013.
- "Clinical Trials" (MSCI-504401): Taught, 2013.

2 At Other Universities and Institutions

- "Computer Packages" (BIOS 511, University of Michigan). Taught, Ann Arbor, MI, 1993, 1994.
- "Longitudinal Categorical Data Analysis Using Generalized Linear Models," Seminar given at the University of Pennsylvania, Philadephia, PA, 1994.
- "Some Aspects of Canonical Correlation Analysis," Seminar given at Syntex Labs, 1994.
- "Incomplete Longitudinal Data Analysis Using Generalized Linear Models," Seminar given at Middle Tennessee State University (The Middle Tennessee Chapter of American Statistical Association), Murfreesboro, TN, 1995.
- "Redundancy Analysis and Its Application to Canonical Analysis of More than Two Vector Variables," Seminar given at the Tamkang University, Taipei, Taiwan, 1995.
- "The Role of the Statistician in the Medical Research," Seminar given at the Tzu Chi Medical College, and National Tung Hua University, Hualien, Taiwan, 1995.
- "A Formula for a Missing Plot in a General Incomplete Block Design, When Recovery of Inter-block Information is Used," Seminar given at the National Cheng Kung University, Tainan, Taiwan, 1995.
- "Statistical Strategies for Modeling the Quasi-Sinusoidality for Time-Qualified Data," Presented at the Technical University, Graz, Austria, 1999.
- "Weighted Three-Stage Cosigner Analysis of Quasi-Sinusoidality of Time-Qualified Data," Seminar given at the Tamkang University, Taipei, Taiwan, 1999.

- "Study Design and Statistical Issues in Clinical Trials," Clinical Trials Protocol Training Course for Bristol-Myers Squibb Inc., Princeton, Wallingford, and Brussels, 2000.
- "Statistics with Applications to the Clinical Trials," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
- "Statistics in Modern Molecular Biology: Protein and RNA Analysis," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
- "Statistical Methods in Longitudinal Data Analysis," lecture given at the Tamkang University, Taipei, Taiwan, 2000.
- "Clustering Methods for the Analysis of Microarray and Protein Expression Data," workshop given at the University of Alabama Comprehensive Cancer Center, Birmingham, AL, 2001.
- "Analysis of cDNA Microarray Expression Data in Human Lung Cancer Using Statistical Class-Prediction Model," lecture given at the University of Alabama Comprehensive Cancer Center, Birmingham, AL, 2001.
- "Statistical Methods for Analyzing the Microarray and Protein Expression Profile Data in Lung Cancer" lecture given at the University of Colorado (Lung SPORE meeting), Denver, CO, 2002.
- "Analysis and Interpretation of Array Data," lecture given at Educational Session in 93rd American Association for Cancer Research Annual Meeting, San Francisco, CA, 2002.
- "Analysis of RNA Expression Patterns in Human Lung Cancer Using Flexible Compound Covariate Method," lecture given at Department of Biostatistics, School of Public Health, University of Alabama, Birmingham, AL, 2002.
- "Analysis and Interpretation of Microarray Data," lecture given at British Columbia Cancer Research Center, Vancouver, Canada, 2002.
- "Weighted Flexible Compound Covariate Method for Classifying Microarray Data," lecture given at National Health Research Institutes, Taipei, Taiwan, 2002.
- "Design, Analysis and Interpretation of Microarray/MALDI-TOF Data," lecture given at Taipei Veterans General Hospital, Taipei, Taiwan, 2002.
- "Quality Filtering: Critical Appraisal and Synthesis of Biomedical Literature" continuing education lecture given at Medical Library Association annual meeting, San Diego, CA, 2003.
- "Statistical Methods for Genomic/Proteomic Pattern Studies," lecture given at the 10th World Conference on Lung Cancer, Vancouver, Canada, 2003.
- "Tumor Proteomic/Genomic Patterns Predict Classification and Tumor Behavior in Human Non-small Cell Lung Cancer", seminar given at Pennington Biomedical Research Center, Baton Rouge, LA, 2003.
- "Statistical Issues in the Era of Proteomics and Genomics Research," lecture given at GI/Pancreas Inter-SPORE Meeting, Nashville, TN, 2004
- "Statistical Issues in the Combinations of the Targeted Therapies in Lung Cancer" lecture given at Targeted Therapies for the Treatment of Lung Cancer Investigators' Meeting, San Diego, CA, 2004.
- "Bioinformatics Tools for High Dimensional Data Analysis," seminar given at the Division of Biostatistics of the National Health Research Institutes, Taiwan, 2004.
- "Analysis of Complex, Multivariate laboratory Data in Epidemiologic Research," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.
- "Biostatistical Analyses of Proteomic and Microarray Data," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.
- "Misclassification, Multiple Comparisons, and Sample Size Requirements," lecture given at the International Epidemiology Institute Course on Molecular Epidemiology, Nashville, TN, 2004.

- "The Challenges of the Statistical Design, Analysis, and Interpretation for High Dimensional Data," lecture given at the Joint NCI-FDA Workshop on Research Strategies, Study Design and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection, Washington DC, 2004.
- "Clinical Trials," AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2004.
- "Data Reduction Approaches for High Dimensional Data Derived from High Throughput Assays," lecture given at the International Society for Biological Therapy of Cancer 19th Annual Meeting, San Francisco, CA, 2004.
- "Design and Analysis of Phase II Clinical Trials," lecture given at the Meharry Medical College MPH Program, Nashville, TN, 2005.
- Recent Development of Computational Research in Quantitative Biomedical Science, A Software Package for MS MALDI-TOF Data Processing, seminar given at the EPSCOR Mini-symposium, Murfreesboro, TN, 2005.
- "Mass Spectrometry Data Processing using wavelets," lecture given at the 2005 AMS Spring Southeastern Sectional Meeting, Bowling Green, KY, 2005.
- "Bioinformatics Tools for Analyzing the Genomic/Proteomic Data," lecture given at the Mouse Models of Human Cancers Consortium Annual Meeting, Nashville, TN, 2005.
- "Bioinformatics, Biostatistics and Biomarkers," lecture given at the Mathematical Biosciences Institute (MBI) Workshop - Genomics, Proteomics, and Bioinformatics - Biomarkers in Cancer Research, Columbus, OH, 2005
- "The Statistical Challenges for Genomic/Proteomic Data Analysis," lecture given at the ICSA 2005 Applied Statistics Symposium, Washington DC, 2005.
- "Bioinformatics/Statistics/Mathematics and High Dimensional Data - From Genomic to Proteomic Research" lecture given at Shanghai Cancer Research Center, Shanghai, China, 2005.
- "Science of Doing Science Biostatistics/Bioinformatics," seminar given at UT Southwestern Medical Center, Dallas, TX, 2005.
- "Clinical Trials," AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2005.
- "Conquering Colorectal Disparities: Molecular Techniques & Examples of How They Can Be Used to Address Cancer Disparities," lecture given at Meharry-Vanderbilt Alliance, Franklin, TN, 2005.
- "MALDI TOF MS Data Processing Using Wavelets, Splines, and Statistical Techniques", AMS Sectional Meeting, Western Kentucky University, Bowling Green, Kentucky, 2005.
- "Biostatistical and Bioinformatics Approaches in High Dimensional Data Derived from High Throughput Assays: A Consumer Guide", tutorial given at The Fourth Asia Pacific Bioinformatics Conference, National Taiwan University, Taipei, Taiwan, 2006.
- "Statistical Challenges for Case-Cohort Study", seminar given at Danish Cancer Society, Copenhagen, Denmark, 2006.
- "Statistical Challenges in Genomic and Proteomic Cancer Research," lecture given at the Radiation Therapy Oncology Group (RTOG) Annual Meeting, Miami, FL, 2006.
- "Biological outcome measures in clinical trials," education session lecture given at the American Society Clinical Oncology (ASCO) Annual Meeting, Atlanta, GA, 2006.
- "The Statistical Issues in Proteomics Data Analysis," seminar given at The University of Texas MD Anderson Cancer Center (MDACC) Bioinformatics Workshop, Houston, TX, 2006.
- "Adaptive Trial Design and Data Analysis", seminar given at Tokai University, Japan, 2006.
- "Clinical Trials" taught at Tokai University, Japan, 2006.

- "A Lesson We Learn from the High Dimensional Data Generated from High Throughput Assays", seminar given at Mayo Clinic, Rochester, MN, 2006.
- "The Statistical Challenges for Clinical Trials Design in High Dimensional Biomarkers" seminar given at Duke University, Durham, NC, 2006.
- "The Wavelet-Based Algorithm for MALDI-TOF MS Data Pre-processing" seminar given at Department of Statistics, National Cheng Kung University, Tainan, Taiwan, 2006.
- "Recent Development of Mass Spectrometry Data Processing Using Mathematical Tools and Statistical Techniques" seminar given at Department of Statistics, Tamkang University, Taipei, Taiwan, 2006.
- "Multiscale Analysis and Proteomic Data Processing", (Joint Presentation w/ Dr. Don Hong), First International Conference on Computational Systems Biology, FuDan University, Shanghai, China, 2006.
- "Introduction to Wavelets and Multiscaling Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the College of Sciences, Ningbo University, Ningbo, Zhejiang, China, 2006.
- "Introduction to Wavelets and Applications in Data Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Mathematical Sciences, Guangxi University of Nationalities, Nanning, Guangxi, China, 2006.
- "Wavelets and Applications in Proteomic Data Analysis", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Computer Informatics Science and Mathematics, Cuiling University of Technology, Guiling, Guangxi, China, 2006.
- "Multiscaling Techniques and PCA/ICA/EMD for Proteomic Data Processing and Biomarkers Discovery", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Center of Artificial Intelligence and Applications, Beihang University, Beijing, China, 2006.
- "Proteomic Data Analysis Using Wavelets and Splines", (Joint Presentation w/ Dr. Don Hong), Seminar given at the Department of Mathematics, Central Florida University, Orlando, Florida, 2006.
- "Clinical Trials," AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2006.
- "Phase II Trial Design and Analysis" lecture given at Meharry Medical College CRECD/MSCI Program, Nashville, TN, 2006.
- "Clinical Trials" taught at Tokai University, Isehara, Japan, 2007.
- "Statistical Challenges in Omic Data Analysis" seminar given at Shanghai Jiaotong University Cancer Research Institute, Shanghai, China, 2007.
- "Biomarkers Clinical Trials Design and Analysis for High-Dimensional Data," seminar given at Bioinformatics Center of Shanghai Institute of Biological Sciences (SIBS) & Chinese Academy of Sciences (CAS), Shanghai, China, 2007.
- "Missing Data Analysis — A Case Study of Denmark Childhood Cancer Survivors Cohort," lecture given at 3rd GCCT Investigators Meeting, Nashville, TN, 2007.
- "Wavelet Methods in Tumor Finger Prints Research", Seminar given at National Cheng Kung University, Taiwan, 2007.
- "Clinical Trials," AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2007.
- "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2007.
- "Science of Doing Science – Bioinformatics & Biostatistics: A Lesson We Learned from Omics Research" Seminar at China Medical University School of Medicine, Taichung, Taiwan, 2008.
- "Biostatistical and Bioinformatics Approaches in High Dimensional Data Derived from High Throughput Assays" Seminar at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.

- "Missing Data Analysis Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
- "Clinical Trials Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
- "Strategy of Multivariate Data Analysis Workshop" lecture given at China Medical University Biostatistics Center, Taichung, Taiwan, 2008.
- "Advanced Clinical Trials Design and Analysis," taught at Tokai University, Isehara, Japan, 2008.
- "The Challenges and Approaches in MALDI-TOF Experiment Design and Preprocessing Procedures," seminar given at Nagoya University School of Medicine, Nagoya, Japan, 2008.
- "Novel Phase II Clinical Trials Design," lecture given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2008.
- "Advanced Statistical Considerations: Things you think you can do, but…," lecture given at ASCO 44th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology, Chicago, IL, May 2008.
- "Design and Analysis of Clinical Trials — Concepts and Methodologies," seminar given at Tokai University, Isehara City, Japan, 2008.
- "Are We Ready to be the New Sheriffs in Town? Some issues of High Dimensional Data Analysis," seminar given at Tamkang University, Taiwan, 2008.
- "Innovative Trial Design for Biomarkers Research," seminar given at NCI Translational Science Meeting, Washington, DC, 2008.
- "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2008.
- "Adaptive Design: A Shortcut to Personalized Medicine?" seminar given at Adaptive Design in Clinical Drug Development Conference, London, England, 2009.
- "Challenges in Biostatistics, Bioinformatics, and Omics Research," seminar given at National Cheng Kung University, Tainan City, Taiwan, 2009.
- "Advanced Clinical Trials Design and Analysis," taught at Tokai University, Isehara, Japan, 2009.
- "Adaptive Design: A Shortcut to Personalized Medicine?" seminar given at Tokai University, Isehara, Japan, 2009.
- "Advanced Statistical Considerations: Things you think you can do, but…," ASCO 45th Annual Meeting, Educational Section of Advanced Concepts in Clincial Trial Design and Methodology, Orlando, FL, 2009.
- "Novel Phase II Clinical Trials Design," lecture given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2009.
- "Advanced Clinical Trials," two-day workshop given at FDA, 2009.
- "Adaptive Design: A Shortcut to Personalized Medicine?" lecture given at ADAPT 2009 conference, Washington, DC, 2009.
- "A Novel Comprehensive Wave-form MS Data Processing Method," seminar given at the 2nd International Congress of Image and Signal Processing (CISP '09)/2nd International Conference on Biomedical Engineering and Informatics (BMEI '09), Tianjin, China, 2009.
- "Omics Era and Its Impact on Biomedical Research: Are we ready to be the new sheriffs in town?" seminar given at Shanghai Center for Bioinformation Technology, Shanghai, China, and Shanghai Jiao Tong University, Shanghai, China, 2009.
- "High Dimensional Data Analysis," taught at Tokai University, Isehara, Japan, 2009.
- "A Shortcut to Personalized Medicine? The power of adaptive designs," seminar given at Adaptive Design in Clinical Drug Development Conference, London, England, 2010.

- "Adaptive Clinical Trials in the Era of Personalized Medicine," seminar given at Tsukuba University, Ibaraki, Japan, 2010.
- "Omics Biomarkers Research: From Experimental Design to Data Analysis," lecture given at 2nd Niagara Lung Cancer Symposium, Niagara-on-the-Lake, Ontario, Canada, 2010.
- "Quantitative Sciences Integration: Future Direction of Biomedical Research in the USA," lecture given at Tokai University School of Medicine, Isehara, Japan, 2010.
- 'High-throughput Biomarker Adaptive Design — A Shortcut to Personalized Medicine?" lecture given at Adaptive Clinical Trials Conference, Washington DC, 2010.
- "Advanced Statistical Considerations: Things you think you can do, but…," ASCO 46th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology, Chicago, IL, May 2010.
- "Novel Phase II Clinical Trials Design," lecture given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2010.
- "Applied Biostatistics and Bioinformatics," 5-day workshop taught at Shanghai Jiao Tong University, Shanghai, China, 2010.
- "Biostatistical Challenges in Omics Research," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.
- "Teaching Biostatistics with Tangible and Interesting Examples," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.
- "Design and Analysis of Translational Research," in Creating Collaborative Research Ethics Education with Costa Rica: Taught, 2011.
- "Advanced Biostatistics," 3-day workshop taught at Kitasato University, Tokyo, Japan, 2011.
- "US FDA case study" special lecture series at International Program for Clinical Research at Kitasato University, Tokyo, Japan, 2011.
- "Quantitative Sciences Integration in the Era of Personalized Medicine Research," seminar given at the International Conference on Applied Statistics, Taipei, Taiwan, 2011
- "Rigorous Quantitative Sciences Integration — the Foundation of the High-Dimensional Genomic Research," seminar given at 4th International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy, New York, 2011.
- "Rigorous Trial Design and the Ethics of Drug Development — Case Studies from US FDA and Duke Medical Center," lecture given at National Yang-Ming University, Taipei, Taiwan, 2011.
- "Rigorous Quantitative Sciences Integration — the Foundation of the Drug Approval in the Personal Genome Era," seminar given at Emerging Information and Technology Conference (EITC), University of Chicago, Chicago, IL, 2011.
- "A Study of the Effect of Radiation Therapy on Mitochondrial DNA Mutation Using Next Generation Sequencing," seminar given at the 9th International Bioinformatics Workshop (IBW2011), Fourth Military Medical School, Xi'an, China, 2011.
- "Advanced Biostatistics," 3-day workshop taught at Shanghai Jiao Tong University, Shanghai, China, 2011.
- "Early Phase Cancer Clinical Trials Workshop — A Road Map for Investigator Initiated Studies," symposium and 3-day workship taught at University of Malaya, Kuala Lumpur, Malaysia, 2011.
- "The Use of Next-Generation Sequencing Technology to Study the Effect of Radiation Therapy on Mitochondrial DNA Mutation," seminar given at Tamkang University, Taipei, Taiwan, 2011.
- "Rigorous Trial Design and Ethics of Drug Development," seminar given at National Tsing Hua University, Hsinchu, Taiwan, 2011.
- "Sample Size Calculation for Differential Expression Analysis of RNA-seq Data Under Poisson Distribution," seminar given at National Cheng Kung University, Tainan, Taiwan, 2011.

- "Advanced Biostatsics," 1-credit course taught at Tamkang University, Taipei, Taiwan, 2011.
- "Omics Data Analysis: Present & Future — From the Era of Gigabyte Data to the Era of Petabyte Data: Are we ready for the next generation sequencing data?" seminar given at National Cancer Center of Tokyo, Japan, 2012.
- "Omics Data Analysis: Present & Future — From the Era of Gigabyte Data to the Era of Petabyte Data: Are we ready for the next generation sequencing data?"12th Annual Targeted Therapy of Lung Cancer Meeting, Santa Monica, CA, 2012.
- "Methods in Cancer Research," 5-day workshop given at Al-Ahsa, Saudi Arabia, 2012.
- "The Challenges of the High-Density Biomarker Adaptive Trials," seminar given at Adaptive Designs in Clinical Drug Development, London, England, 2012.
- "Statistical Bioinformatics Challenges for Clinical Trial Design in the Era of High-Density Data Analysis," seminar given at AACR Annual Meeting, Chicago, IL, 2012.
- "Advanced Biostatistics," 5-day course given at Beijing University, Beijing, China, 2012.
- "Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution," seminar given at Indiana University Bloomington School of Informatics and Computing, 2012.
- "Emerging Methods of Quantitative Biology," seminar given at the Nordic Neuroendocrine Symposium, Nashville, TN, 2012.
- "Introduction to Statistical Methods for High-Dimensional Data Analysis," seminar given at the Workshop for Chronic Disease Epidemiology and Prevention, Shanghai, China, 2012.
- "Recent Developments of the Statistical Bioinformatics Approaches to Designing and Analyzing Sequencing Data," seminar given at the International Workshop on Cancer Systems Biology, Jilin University, Changchun, China, 2012.
- "Novel Phase II Clinical Trials Design," seminar given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2012.
- "Novel Clinical Trial Designs in the Genomic Era," seminar given at the International Congress on Targeted Therapies in Cancer, Washington, DC, 2012.
- "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China, 2012.
- "Adaptive Clinical Trial Design in the Era of High-Density Data Analysis," seminar given at ADAPT Congress 2012, Washington, DC. 2012.
- "Emerging Methods of Quantitative Biology," seminar given at EITA-Bio 2012, Princeton University, Princeton, NJ, 2012.
- "Emerging Methods of Quantitative Biology," seminar given at Moffitt Cancer Center Grand Rounds, Tampa, FL, 2012.
- "Bioinformatics in Oncology Clinical Trials" and "Novel Phase II Design," seminars given at Talent in Oncology Programme, Munich, Germany, 2012.
- "Novel Trial Design for Sequencing Biomarkers," seminar given at 2013 Biomarkers Summit, London, United Kingdom, 2013.
- "Emerging Methods of Quantitative Biology" seminar given at Fudan University, Shanghai, China, 2013.
- "Advanced Biostatistics," 3-day course given at Beijing University, Beijing, China 2013.
- "Novel Phase II Design," seminars given at Talent in Oncology Programme, Amsterdam, Netherlands, 2013.
- "Advanced Biostatistics with R," 5-day course given at Shanghai Jiao Tong University, Shanghai, China 2013.

- "Clinical Trial Designs in the Genomic Era," seminar given at 11th Annual International Congress on Targeted Therapies in Cancer, Washington, DC, 2013.
- "Statistical Bioinformatics Challenges in the Era of Personalized Medicine in Cancer," workship given at Roswell Park Cancer Institute, Buffalo, NY, 2013.
- "Novel Phase II Clinical Trials Design," seminar given at AACR/ASCO Workshop Methods in Clinical Cancer Research, Vail, CO, 2013.
- "Advanced Biostatistics," 5-day course given at Tamkang University, Taipei, Taiwan, 2013.
- "Advanced Biostatistics with R," 3-day course given at National Institute of Biological Sciences, Beijing, China, 2014.
- "Bioinformatics in oncology clinical trials" and "Reporting and interpreting statistics in clinical trial research," seminars given at Talent in Oncology Programme, Munich, Germany, 2014.

3 Web-Based Courses

- "Basic Study Design in Clinical Trials", Bristol-Myers Squibb Protocol Training Course, 2002. http://www.midicorp.com/extranet/frameset.html
- "Bias Reduction in Clinical Trials", Bristol-Myers Squibb Protocol Training Course, 2002. http://www.midicorp.com/extranet/frameset.html
- "Trial Setup/Monitoring Considerations in Clinical Trials", Bristol-Myers Squibb Protocol Training Course, 2002. http://www.midicorp.com/extranet/frameset.html

4 Mentoring

- (b) (6)

- [redacted] (b) (6)

ACADEMIC SERVICE

1. **Have refereed papers for the following journals**
   a. *Journal of American Statistical Association*
   b. *Communications in Statistics*
   c. *Biometrical Journal*
   d. *American Medical Informatics Association*
   e. *Information Sciences: An International Journal*
   f. *New England Journal of Medicine (with Dr. David Johnson)*
   g. *Cancer*
   h. *Cancer Research*
   i. *Southern Medical Journal*
   j. *Arteriosclerosis, Thrombosis, and Vascular Biology*
   k. *International Chinese Journal of Dentistry* (**Editorial Board Member**)
   l. *Clinical Pharmacology and Therapeutics*
   m. *Journal of Concrete and Applicable Mathematics* (**Guest Editor with Prof. Don Hong)**
   n. *BMC Bioinformatics*
   o. *Clinical Cancer Research* (**Editorial Board Member**)
   p. *Technology in Cancer Research and Treatment*
   q. *Proteomics*
   r. *Proceedings of the National Academy of Sciences*
   s. *Cancer Prevention Research Journal* (**Editorial Board Member**)
   t. *Computational Statistics and Data Analysis*
   u. *Journal of Applied Statistics*
   v. *Biological Procedures Online* (**Editorial Board Member**)
   w. *Clinical Trials*
   x. *Journal of Clinical Oncology* **(Editorial Board Member)**
   y. *Carcinogenesis* (**Editorial Board Member**)

z. *Science Translational Medicine*

aa. *Proteomics — Clinical Applications*

bb. *Dataset Papers in Medicine*

cc. *PLoS ONE* (**Statistical Advisory Board Member)**

dd. *Journal of Thoracic Oncology* (**Associate Editor**)

ee. *Journal of Computational Systems Biology* (**Editorial Board Member**)

2. American Statistical Association

a. International Science and Engineering Fair (ISEF): Special Awards Judge for American Statistical Association, 1997.

b. Mid-Tennessee Chapter: Council Representative, 1998 – 1999.

c. Mid-Tennessee Chapter: President, 1999.

d. Council of Chapter Office: Vice Chair Candidate, 2001.

e. Council of Chapters Governing Board: Vice Chair, 2002 – 2004.

f. Council of Chapters Nominations Committee: Member, 2004 – 2005.

g. Council of Chapters: Candidate for Chair Elect Position, 2010.

3. Society for Epidemiologic Research

a. Annual Meeting Abstracts Reviewer, 1997.

b. Annual Meeting Abstracts Reviewer, 1998.

c. Annual Meeting Abstracts Reviewer, 1999.

4. National Cancer Institute

a. NCI Study Section Special Emphasis Panel (ZCA1 SRRB-X (CC)): Member, 1999.

b. NCI Subcommittee D-Clinical Studies Review Panel (P01-CA72008-04): Member, 2000.

c. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Studies Review Panel (P01-CA88961-01): Member, 2000.

d. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Wisconsin, Madison): Member, 2000.

e. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Studies Review Panel (NCI-E GRB-R(Y)): Member, 2001.

f. NCI Subcommittee C-Basic and Preclinical Review Panel (NCI-C GRP-P (Q2)): Member, 2001.

g. NCI 9th SPORE Investigators' Workshop: Invited Speaker, 2001.

h. NCI Lymphoma Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2002.

i. NCI Lung SPORE Annual Meeting, Denver, Colorado, Session of Methods of Array Analysis: Chair, 2002.

j. NCI PO1-CA096888-01C4 "Molecular Gene and Radiation Therapies for Cancer" site visit reviewer: Member, 2002.

k. NCI Special Emphasis Panel of Biology and Transplantation of Human Stem Cell (ZCA1 GRB-W(01)): Member, 2002.

l. NCI Subcommittee E-Cancer Epidemiology, Prevention & Control Review Panel (NCI-E GRB-P (K2)): Member, 2002.

m. NCI Subcommittee C — Basic & Preclinical Review Panel (NCI-C GRB-P (K1)): Member, 2002.

n. NCI PO1-CA100336-01 Review Panel "Molecular Targets in Prostate Cancer": Member, 2002.

o. NCI Pancreatic Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.

p. NCI PO1 CA 104668-01 Review Panel "Mechanism-Based Approach for the Management of Prostate Cancer" (NCI-C GRB-P (X8)): Member, 2003.

q. NCI Ovarian & Breast Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.

r. NCI PO1 CA 104106-01 Review Panel "Signaling and Progression in Prostate Cancer" (NCI-C GRB-R (C2)): Member, 2003.

s. NCI Leukemia & Lymphoma Specialized Programs of Research Excellence (SPORE) Review Panel: Member, 2003.

t. NCI Developmental Therapeutics Study Section: Member, 2003 – 2008.

u. NCI UO1 CA 107948-01 Review Panel "The Pediatric Brain Tumor Consortium" (NCI – ZCA1 GRB-F (J1)): Member, 2003.

v. NCI Subcommittee D — Clinical Studies PO1 CA112359-01 Review Panel "New Approaches to the Treatment of Neuroblastomas" (NCI-D RPRB (S3)): Member, 2004.

w. NCI Subcommittee A — Cancer Centers review panel (NCI-A RTRB-Z (E1)), 2004.

x. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Pennsylvania Comprehensive Cancer Center): Member, 2004.

y. NCI GI/Pancreas Inter-SPORE Meeting: Section of Data Analysis: Chair, Nashville, TN, 2004.

z. NCI GI/Pancreas Inter-SPORE Meeting: Invited Speaker, Nashville, TN, 2004

aa. NCI Clinical Oncology Study Section: Ad Hoc Member, 2005.

bb. NCI Specialized Programs of Research Excellence (SPORE) in Ovarian — GYN Cancer Review panel: Member, 2005.

cc. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Colorado Comprehensive Cancer Center): Member, 2005.

dd. NCI Etiologic and Early Marker Studies (EEMS) Review Panel: Member, 2005 – present.

ee. NCI Avon Breast Cancer Research Review Panel: Member, 2005.

ff. NCI PO1 Experimental Therapeutics Cluster Review Panel: Member, 2005.

gg. NCI ZCA1 GRB-S (01) Centers of Cancer Nanotechnology Excellence (CCNE). National Cancer Institute Special Emphasis Panel: Member, 2005.

hh. NCI ZRG1 ONC-J (02)M: COX-2 Inhibition of T-Cells in Human Lung Cancer. Center for Scientific Review Special Emphasis Panel: Member, 2005.

ii. NCI Translational Research Workshop Group (TRWG): Invited Speaker, 2006.

jj. NCI Intramural Program: Biostatistics Branch Review Panel: Member, 2006.

kk. NCI SPORE Breast Cancer Research Review Panel: Member, 2006.

ll. NCI Avon Breast Cancer Research Review Panel: Member, 2006.

mm. NCI Special Emphasis Panel (SEP) L30 and L40: Member, 2006 – 2009.

nn. NCI Discovery and Development Special Emphasis Panel (SEP): Member, 2006 – 2007.

oo. NCI Specialized Programs of Research Excellence (SPORE) Standing Special Emphasis Panel (SEP): Member, 2007 – present

pp. NCI Workshop on Implementation of Biomarkers Evidence in Translational Research Organizing Committee: Member, 2007.

qq. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Kimmel Cancer Center at Thomas Jefferson University): Member, 2007.

rr. NCI Avon Progress for Patients Blue Ribbon Panel Advisory Board: Member, 2007.

ss. NCI/NIH Cancer Genome Atlas (TCGA) Data Portal Use Workshop: Invited participant, 2008.

tt. NCI Special Emphasis Panel on Comprehensive Systems Genetics of Cancer: Member, 2008.

uu. NCI P01 Molecular Oncology Special Emphasis Panel: Member, 2008.

vv. NCI Translational Science Meeting: Invited Speaker, 2008.

ww. NCI Subcommittee J — Population and Patient-Oriented Training Study Section: Member, 2008 – 2009.

xx. NCI ZCA1 RTRB-2 Career Development Awards Panel: Member, 2008.

yy. NCI P01 Molecular Oncology (Basic, Translational, and Clinical Studies) Special Emphasis Panel: Member, 2009.

zz. NCI P01 Molecular Oncology (Basic, Translational, and Clinical Studies) Special Emphasis Panel: Member, 2010.

aaa. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Pennsylvania State Cancer Center): Member, 2010.

bbb. NCI SBIR Phase II, Integrating patient-reported outcomes in hospice and palliative care practices, Study section: Chair, 2010.

ccc. NCI LRP Review Panel: Member, 2011.

ddd. NCI Cancer Diagnostics and Treatments SBIR/STTR review panel: Member, 2011.

eee. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Maryland Greenebaum Cancer Center): Member, 2011.

fff. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (University of Virginia Cancer Center): Member, 2011.

ggg. NCI P50 Cancer Center Support Grant (CCSG) Review Panel (Johns Hopkins Kimmel Cancer Center): Member, 2012.

hhh. NCI P01 ZCA1 GRB-T (M1) Special Emphasis Panel: Member, 2012.

iii. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (New York University Cancer Institute): Member, 2012.

jjj. NCI P30 Cancer Center Support Grant (CCSG) Review Panel (Chicago University Cancer Center): Member, 2012.

kkk. NCI Cancer Immunopathology and Immunotherapy (CII) Study Section: Member, 2013-2017.

5. VICC Clinical Breast Cancer Journal Club: Statistical Commentator, 1998 – present.

6. (b) (6)

7.

8. NIH SRA, MEP Study Section Special Emphasis Panel (ZRG1-MEP-04S): Member, 1999.

9. U.S. Army Medical Research and Materiel Command (USAMRMC) Breast Cancer Research Program (BCRP): Scientist Reviewer, Epidemiology, 1999.

10. International Biometric Conference, Berkeley, California, Section of Correlated Binary Data: Chair, 2000.

11. Vanderbilt University School of Medicine Admission Interview Process: Faculty Interviewer, 2000 – 2001.

12. Joint Statistical Meetings Invited Sessions Program: Section on Statistical Consulting: Organizer, 2001.

13. Joint Statistical Meetings Invited Sessions Program: Invited Speaker, 2001.

14. International Chinese Statistical Association: Section on Recent Statistical Research in Cancer Studies: Invited Speaker, Philadelphia, PA, 2002.

15. American Association for Cancer Research (AACR): Education Session of Array and Gene Expression: Invited Speaker, San Francisco, CA, 2002.

16. International Association for the Study of Lung Cancer: Symposium of Molecular Taxonomy of Lung Cancer: Invited Speaker, Vancouver, BC Canada, 2003.

17. American Association for Cancer Research (AACR) International Conference on "Frontiers in Cancer Prevention Research": Scientific Committee Member, Phoenix, AZ, 2003.

18. 2004 Targeted Therapies for the Treatment of Lung Cancer Investigators' Meeting: Invited Speaker, San Diego, CA, 2004.

19. 2004 American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2004.

20. International Epidemiology Institute 2004 Course on Molecular Epidemiology: Invited Faculty Member, Nashville, TN, 2004.

21. Joint NCI-FDA Workshop on Research Strategies, Study Design and Statistical Approaches to Biomarkers Validation for Cancer Diagnosis and Detection: Invited Faculty, Washington DC, 2004.

22. International Society for Biological Therapy of Cancer 19th Annual Meeting: Invited Speaker, San Francisco CA, 2004.

23. IASLC/ASCO Consensus Conference on Bronchioloaveolar Cell Carcinoma: Invited Panel Discussant, New York, NY, 2004.

24. Targeted Therapies for the Treatment of Lung Cancer Investigators' Meeting: Invited Faculty, Steamboat Springs, CO, 2005.

25. American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2005.

26. Mathematical Biosciences Institute (MBI) Workshop — Genomics, Proteomics, and Bioinformatics — Biomarkers in Cancer Research: Invited Faculty, Columbus, OH, 2005.

27. ICSA 2005 Applied Statistics Symposium: Invited Faculty, Washington DC, 2005.

28. Spline and Wavelet Applications in Biostatistics and Actuarial Mathematics, (With Dr. Don Hong). Invited presentation and Minisymposium Organizer, Athens, GA, 2005.

29. 11th World Conference on Lung Cancer, Invited Speaker, Barcelona, Spain, 2005.

30. 47th Anniversary Annual Conference, The American Associate for Chinese Studies: Chair and local organizing committee: Member, Nashville, TN, 2005.

31. NIH National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel: Member, 2005.

32. Workshop on Mathematical Tools and Statistical Techniques for Quantitative Medical Data Analysis. Scientific Committee, Member, 2005.

33. Radiation Therapy Oncology Group (RTOG) Annual Meeting: Invited Speaker, Miami, FL, 2006.

34. American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2006.

35. 42nd American Society Clinical Oncology (ASCO) Annual Meeting: Invited Faculty Member, Atlanta, GA, 2006.

36. 4th Asia Pacific Bioinformatics Conference, Invited Tutorial Speaker, Taipei, Taiwan, 2006.

37. NSA Workshop on Mathematical Tools and Statistical Techniques for Quantitative Medical Data Analysis, Scientific Committee: Member, Johnson City, TN, 2006.

38. Hawaii International Conference on Statistics, Math, and Related Fields: Abstract Reviewer, Section Chair, Honolulu, HI, 2007.

39. 6th-Sino-Japan-Korea Bioinformatics Training Course: Invited Faculty, Shanghai, China, 2007.

40. American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2007.

41. FDA Office of Women's Health Intramural Science Program: Expert Reviewer, 2007.

42. 12th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, Seoul, Korea, 2007.

43. NSF Workshop on Quantitative Proteomic Data Analysis: Invited Plenary Speaker, Murfreesboro, TN, November 2007.

44. 2nd Adaptive Designs in Clinical Drug Development: Invited Speaker, London, UK, 2008.

45. Targeted Therapies for the Treatment of Lung Cancer Meeting: Invited Speaker, Santa Monica, CA, February 2008.

46. Susan G. Komen Foundation Promise Grant: Program Reviewer, Washington, DC, 2008.

47. ENAR, Panel on Genomics and Microarray Analyses: Chair, Arlington, VA, 2008.

48. AACR Annual Meeting 2008, "Clinical Trial Design Workshop Part 1: A Journey from Classical to Innovative Approaches": Invited Panel Member, San Diego, 2008.

49. 2008 Biostatistics and Bioinformatics Workshop on High Dimensional Data Analysis: Co-Organizer, Taipei, Taiwan, 2008.

50. Lung Cancer Symposium 2008, Invited Speaker, Niagara-on-the-Lake, Ontario, Canada, 2008.

51. AACR Annual Meeting 2008: Invited Faculty, San Diego, 2008.

52. ASCO 44th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Chicago, IL, May 2008.

53. American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2008.

54. 13th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, San Francisco, 2008-2009.

55. American Association for Cancer Research (AACR) 2009 Program Committee, Biostatistics in Clinical Trials Section: Chair, 2008.

56. Susan G. Komen for the Cure's Promise Grants Scientific Peer Review Committee: Member, 2008 – 2012.

57. American Society for Clinical Oncology Cancer Research Committee: Member, 2008 – present.

58. Canadian Cancer Society Research Institute Program Project Review Panel: Member, 2009.

59. ASCO 45th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Orlando, FL, 2009.

60. 13th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, San Francisco, 2009.

61. NIH/CSR ZRG1 OTC-X(14)B Experimental Cancer Therapeutics SBIR/STTR study section: Member, 2009.

62. AACR/ASCO Capitol Hill Lobby Day: Member, 2009.

63. American Association for Cancer Research/American Society of Clinical Oncology Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2009.

64. American Association for Cancer Research 8th Annual International Conference on Frontiers in Cancer Prevention Research: Scientific Review Committee Member, 2009.

65. NIH/CSR ZRG1 OTC-X (14)B Experimental Cancer Therapeutics SBIR/STTR Study section: Member, 2010.

66. Susan G. Komen for the Cure Targeted Therapies (TT2) grant: Review panel member, Dallas, TX, 2009.

67. NIH Gastrointestinal Cancers Special Emphasis Panel: Member, 2010.

68. Cancer Society Research Institute, Review Panel for the Canadian Breast Cancer Research Alliance Special Research Competition on Predictive Oncology, Member, 2010.

69. 2nd Lung Cancer Symposium, Invited Speaker, Niagara-on-the-Lake, Ontario, Canada, 2010.

70. ASCO 46th Annual Meeting, Educational Section of Advanced Concepts in Clinical Trial Design and Methodology: Invited Speaker, Chicago, IL, May 2010.

71. Susan G. Komen for the Cure Research Programs grant: Review panel member, Dallas, TX, 2011.

72. AACi/AACR/ASCO Capitol Hill Lobby Day: Member, 2010.

73. American College of Radiology Imaging Network Biospecimen Review Committee: Member, 2010 – present.

74. American Society for Clinical Oncology Cancer Foundation Grants Selection Committee: Member, 2010 – present.

75. The 9th International Bioinformatics Workshop (IBW2011): Invited Speaker, Xi'an, China, 2011.

76. 4th International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy: Biomarkers and Informatics: Session Chair, New York, 2011.

77. 14th World Conference on Lung Cancer, International Association for the Study of Lung Cancer: International Scientific Committee: Member, Amsterdam, Netherlands, 2011.

78. AACR/ASCO Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2011.

79. 2012 AACR Annual Meeting Scientific Program Committee: Member, 2011.

80. International Workshop on Cancer Systems Biology (ICSB) Steering Committee: Member, 2011 – present.

81. Aduro BioTech CRS-207 & GVAX Pancreas Vaccine with Cyclophosphamide Study Data and Safety Monitoring Committee: Member, 2011.

82. Immunogen Data Safety and Monitoring Board: Member, 2012.

83. Talent in Oncology Programme (TOP): Invited Speaker, Munich, Germany, 2012.

84. 2012 Chicago Thoracic Symposium: Absract Reviewer, Program Committee Member, and Chair of Keynote Lectures, 2012.

85. AACR/ASCO Workshop Methods in Clinical Cancer Research: Invited Faculty Member, Vail, CO, 2012.

86. 2012 Methods in Cancer Research Workshop, Scientific Committee: Member, Al-Ahsa, Saudi Arabia, 2012.

87. 2012 AACR Annual Meeting, Clinical Trial Design in the Era of High-Density Data Analysis Session: Chairperson, 2012.

88. International Conference on Intelligent Biology and Medicine: General Chair, Nashville, TN, 2012.

89. Talent in Oncology Programme (TOP): Invited Speaker, Amsterdam, Netherlands, 2013.

90. AACR/ASCO Workshop Methods in Clinical Cancer Research: Co-Chair, Vail, CO, 2013.

91. 11th Annual International Congress on Target Therapies in Cancer: Invited Speaker, Washington, DC, 2013.

92. International Conference on Intelligent Biology and Medicine: General Chair, Nashville, TN, 2013.

93. Brain Tumour Charity, Peer Review Committee: Member, 2013.

94. 2014 AACR Program Committee, Clinical Research Subcommittee: Chairperson of the Biostatistics in Clinical Trials, 2014.

95. Grand Rounds, Roswell Park Cancer Institute: Invited Speaker, Buffalo, NY, 2013.

96. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer: Invited Speaker, Syndey, Australia, 2013.

97. International Clinical Trials Workshop (ICTW) Working Group: Member, 2014 – 2017.

98. (b) (4)

COMMITTEES

Vanderbilt University

- Vanderbilt University Faculty Senate, 2004 – 2007.
- Vanderbilt Community Giving Campaign Allocations Committee: member, 2006 – 2007.
- Vanderbilt Senate Consultative Committee member, 2007.
- Vanderbilt Academic Policies and Services Committee (APS): member; 2004 – 2007.
- Vanderbilt Academy for Excellence in Teaching: member, 2013 – present.

Vanderbilt University School of Medicine

- Vanderbilt-Ingram Comprehensive Cancer Center Clinical Protocol Review Committee: Member, 1995 – 2001.
- Vanderbilt-Ingram Comprehensive Cancer Center Clinical Trials Office Steering Committee: Member, 1998 – present.
- Vanderbilt-Ingram Comprehensive Cancer Center Biostatistics Faculty Search Committee: Chairman, 1998.
- Information Policy Advisory Committee Database Subcommittee: Member, 1999.
- Bioinformatics Graduate Programs Admissions Committee: Member, 2001.
- Data Center for Large Clinical Trials Multidisciplinary Group Committee: Member, 2001 – present.
- Vanderbilt-Ingram Comprehensive Cancer Center Data Safety and Monitoring Committee: Member, 2001 – present.
- Vanderbilt-Ingram Comprehensive Cancer Center Clinical Protocol Scientific Review Committee: Member, 2001 – present.
- Vanderbilt University Faculty Mentoring Committee: Ayumi Shintani, Ph.D., Health Services Research/Biostatistics, 2001 – 2007.
- Vanderbilt University Faculty Mentoring Committee: Terri Ni, Ph.D., Genetic Medicine/ Cardiovascular Medicine, 2003 – 2009.
- Vanderbilt University Faculty Mentoring Committee: Andrew Yi, Ph.D., Genetic Medicine, 2007 – present.
- Data Safety and Monitoring Committee: RAAS, Inflammation and Post-Operative Atrial Fibrillation, member, 2003 – present.

- Vanderbilt University Department of Biostatistics, Promotion and Tenure Committee: Member, 2003 – present.
- Vanderbilt University Department of Biostatistics, Faculty and Search Committee: Member, 2003 – present.
- Vanderbilt University Microarray Core Steering Committee: Member, 2006 – present.
- Ayers Institute Steering Committee: Member, 2008 – present.
- Data Safety and Monitoring Board: Inotropic Drugs and Risk of Postoperative Atrial Fibrillation: Member, 2009 – present.
- Data Safety and Monitoring Board: Antioxidant Enzyme Induction as a New Approach to Therapy in Patients with Asthma: Member, 2009 – present.
- Emerging Information and Technical Conference (EITC) Biomedical Technology Steering Committee: Member, 2011 – present.
- BioVU Steering Committee: Member, 2012 – present.

Meharry-Vanderbilt Alliance

- Epidemiology & Statistics Senior Faculty Search Committee: Co-Chair, 2001 – 2002.
- Statistics Senior Faculty Search Committee: Co-Chair, 2013.

University of Alabama at Birmingham Comprehensive Cancer Center

- External Advisory Board: Ad-Hoc Member, 2003.
- External Consultant for Bioinformatics, 2003.

American Joint Committee on Cancer (AJCC)

- Statistical Task Force Committee: Member, 2005.
- Statistical Task Force, Development of the 7th Edition of the AJCC Cancer Staging Manual: Member, 2006.

Middle Tennessee State University

- College of Basic and Applied Science, Master of Science in Professional Science (MS-PS) Advisory Board: Member, 2006 – present.

State of Tennessee Department of Health

- Tennessee Cancer Registry Advisory Committee: Member, 2007 – present.

Northwestern University

- Robert H. Lurie Comprehensive Cancer Center External Advisory Board: Member, 2008 – present.

SRA International Global Health Sector

- External Consulting and Advisory Team: Member, 2008 – present.

US Food and Drug Administration (FDA)

- Anti-infective Drugs Advisory Committee: Voting member, 2009 – present.

Tokai University Insitute of Innovative Science and Technology, Isahara, Japan

- Tenure Track Faculty Selection Committee: Member, 2010 – present.

Shanghai Center for Bioinformatics Technology, Shanghai, China

- Academic Committee Member: Member, 2010 – present.

University of Colorado, Denver

- SPORE in Lung Cancer External Scientific Advisory Board Member, 2010 – present.
- Lung Strategic Partnering to Evaluate Cancer Signatures (SPECS) External Advisory Committee: Member, 2011 – present.

University of Kentucky Markey Cancer Center, Lexington

- Biostatistics Shared Resource Facility External Advisory Board Member, 2010 – present.

American College of Radiology

- Imaging Network Biospecimen Review Committee: Member, 2010 – present.

Moffitt Cancer Center

- External Advisory Baord: Member, 2014 – present.
- Council of Scientific Advisors Ad-Hoc Member, 2010.
- SPORE in Lung Cancer External Scientific Advisory Board Member, 2010 – present.

Duke University

- Institute for Genome Sciences and Policy (Duke IGSP): Data Safety and Monitoring Board-Oversight Committee (DSMB-OC), 2011 – 2012.

Arizona University

- Arizona GI SPORE External Advisory Committee: Member, 2011 – present.

Dartmouth College

- Institute for Quantitative Biomedical Sciences External Advisory Committee: Member, 2012 – present.

Cancer Institute of New Jersey / Rutgers University Precision Medicine Initiative

- External Advisory Board: Member, 2013 – present.

Radiation Therapy Oncology Group, American College of Radiology

- Brain SPORE External Advisory Board: Member, 2013 – present.

City of Hope Cancer Center

- Biostatistics Core External Advisory Board: Member, 2013 – present.

University of California, San Diego

- Cancer Center Support Grant: Biostatistics Core External Consultant, 2013.

Mount Sinai School of Medicine

- Tisch Cancer Institute External Advisory Board: Member, 2013 – present.

United States-Latin America Cancer Research Network

- Data Monitoring Committee (DMC) in the Molecular Profiling of Breast Cancer Study, 2013 – present.

MD Anderson Cancer Center

- External Advisory Board (EAB) (Scientist Panel) of the R. Lee Clark Fellows Award, 2014 – present.

LEADERSHIP DEVELOPMENT

- Vanderbilt University School of Medicine Academic Leadership Program, 2007.

CONSULTING

- Vanderbilt University Medical Center — Have provided consulting services to over 750 clients and have reviewed 1,400 clinical protocols, 1994 – present.

CURRENT RESEARCH AT VANDERBILT

U01 CA163056 (Shyr) 09/01/11-08/31/16
NCI Role: Principal Investigator
Barrett's esophagus translational research network coordinating center (BETRNetCC)
The major goals of this project are to coordinating functioning of the BETRNet; to facilitate data collection, management, analysis, and dissemination across the BETRNet; to develop a multi-institutional patient registry/virtual biorepository for the BETRNet; and to develop and apply evaluation metrics for the BETRNet.

National Lung Cancer Partnership (Shyr) 08/01/12-07/31/14
National Lung Cancer Partnership Role: Principal Investigator
Lung Cancer Mutation Consortium Protocol
The major goal of this project is to develop and implement a customized clinical relational database for use by the Lung Cancer Mutation Consortium.

P50 CA098131 (Arteaga) 09/11/08-05/31/14
NCI Role: Core leader
SPORE in breast cancer
The major goal of this project is to address basic, clinical, and population research questions in

breast cancer.

P50 CA095103 (Coffey) 07/25/07 – 04/30/17
NIH/NCI Role: Core leader
SPORE in GI Cancer
The major goal of this project is to investigate the molecular features of gastrointestinal tumors.

P30 CA068485 (Pietenpol) 09/10/10 – 08/31/15
NIH/NCI Role: Core leader
Cancer Center Support Grant
The major goal of this project is to coordinate cancer-related activities of Vanderbilt University.

R01 CA092447 (Blot) 07/26/11 – 06/30/16
NCI Role: Co-Investigator
Southern Community Cohort Study
Southern Community Cohort Study, a long-term prospective epidemiologic study tracking cancer incidence among approximately 86,000 adults age 40-79, two-thirds African American. Nested case-control studies will utilize baseline questionnaire data and stored biologic specimens to address unanswered questions about the causes of cancer among African Americans and the determinants of health disparities.

U54 CA163072 (Moses) 09/01/11 – 08/31/16
NCI Role: Co-Investigator
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities
The major goal of this study is to create a comprehensive cancer research partnership between Meharry Medical Center (MMC) and Vanderbilt-Ingram Cancer Center (VICC).

R21 NS080639 (DeBaun) 09/30/12 – 08/31/14
NINDS Role: Co-Investigator
Primary Prevention of Strokes in Nigerian Children with Sickle Cell Disease
The goal of this project is to determine the acceptability of randomization to HU vs. placebo for primary prevention of strokes in Nigerian children with sickle cell anemia (SCA) in preparation for a NIH sponsored multicenter, phase III Trial.

R01 CA034590 (Richmond) 07/01/13-06/30/18
NCI Role: Co-Investigator
Chemokine signals in the pre-metastatic niche inhibit metastasis
The major goal of this project is to evaluate mechanisms of entrainment and to characterize the precise intracellular signal transduction pathways involved in chemokine mediated entrainment of leukocytes associated with progression of breast cancers.

R01 CA174853 (Epplein) 07/01/13-06/30/18
NCI Role: Co-Investigator
Heliobacter pylori blood biomarker for gastric cancer risk in East Asia
The major goal of this project is to build develop a model for gastric cancer risk in East Asia that includes H. pylori blood biomarkers and enables us to categorize individuals into high and low-risk groups for gastric cancer.

UM1 CA173640 (Shu) 09/18/13-08/31/18
NCI Role: Co-Investigator
Shanghai Men's Health Study
The major goal of this project is to conduct a long-term epidemiological study of cancer and other chronic diseases, with a focus on identifying modifiable protective dietary factors for cancers. The SMHS, with its large sample size, wealth of resources, and unique exposure patterns and disease spectrum, provides exceptional opportunities to address many significant hypotheses that cannot be adequately investigated in any other existing cohort study.

R01 CA177372 (El-Rifai) 08/01/13-07/31/16

NCI Role: Co-Investigator
The role of miRNA network in gastric cancer
The goal of this project is to gain further understanding of the role of H. Pylori in shaping the miRNA signature and promoting the multi-step gastric tumorigenesis in order to identify diagnostic, prognostic and possibly therapeutic miRNA targets in gastric cancer.

Past

R01 CA102162 (Moses) 12/01/11 – 11/30/13
NCI Role: Co-Investigator
TGF-Beta in Mammary Development and Tumorigenesis
The major goal of this study is to characterize Cre expression pattern, recombination, and phenotype in various TGF-beta recombinant mouse backgrounds.

P50 CA128323 (Gore) 09/22/08 – 08/31/13
NCI Role: Core leader
Vanderbilt *in vivo* Cellular and Molecular Imaging Center
The major goal of this project is to establish a new *in vivo* cellular and molecular imaging center at Vanderbilt University, which will be dedicated to highly innovative molecular imaging studies of cancer biology.

P50 CA090949 (Carbone) 09/26/07 – 03/31/12
NIH/NCI Role: Core leader
SPORE in Lung Cancer
The major goal of this project is to investigate the molecular features of tumors or tumor-host interactions that determine their clinical behavior and represent potential molecular targets for interventions.

RC2 CA14839 (Pao: Colorado) 09/01/09 – 08/31/13
NIH
Lung Cancer Mutation Consortium Trial Role: Core leader
The major goal of this project is to establish a Lung Cancer Mutation Consortium (LCMC) consisting of 13 institutions with a major interest in lung cancer and genomic testing of lung cancer as documented by having major NCI grants in lung cancer.

U54 CA091405 (Moses) 09/25/06 – 07/31/12
NIH/NCI Role: Co-Investigator
MMC and VICC: Partners in Eliminating Cancer Disparities
A comprehensive cancer research partnership between MMC and VICC.

2R01 CA085492 (Moses) 03/01/11 – 02/29/16
NCI Role: Co-Investigator
TGF-beta suppression and promotion of mammary carcinomas
The major goal of this project is to delineate the mechanisms of both suppression and promotion of mammary tumors by TGF-beta, using mouse models.

P01 CA116087 (Peek) 01/01/09 – 12/31/13
NCI Role: Co-Investigator
H. pylori-induced Inflammation and Gastric Cancer
The major goal of this project is to delineate the molecular signaling events initiated by *H. pylori*-epithelial cell contact that regulate phenotypes related to gastric carcinogenesis.

U54 CA126505 (Matrisian) 09/25/06 – 08/31/11
NIH/NCI Role: Co-Investigator
Paracrine TGF-Beta Signaling in Tumor Initiation and Progression
The major goal of this project is to establish the Vanderbilt University Tumor Microenvironment Network (VUTMEN) to contribute to the generation of a comprehensive understanding of the role of the tumor stroma.

R01 DK058587 (Peek) 09/01/07 – 06/30/11
NIDDKD Role: Core leader
H. pylori and Gastrointestinal Biology
The major goal of this project is to investigate effects of *H. pylori* on prostaglandin biology using conditionally immortalized gastric cells.

R01 CA085492 (Moses) 12/15/05 – 11/30/10
NCI Role: Co-Investigator
TGF-Beta Suppression and Promotion of Mammary Carcinomas
The specific aim for this gran is to determine the effects of systemic inhibition of TGF-(signaling on mammary tumor formation and metastases from MMTV-c-neu and MMTV-PyVmT-induced mammary tumors in the context Tgfbr2 knockout in mammary epithelial cells effected by both MMTV-Cre and WAP-Cre.

U01 CA114771 (Carbone) 09/30/05 – 05/31/10
NCI Role: Co-Investigator
Molecular Signatures of Lung Cancer
This team proposes to evaluate the potential clinical usefulness of several molecular signatures already developed using a variety of molecular analysis technologies, including DNA, RNA and protein-based technologies addressing both diagnostic and predictive signatures. Important markers in proteomic profiles will be identified, and together with genomic and cDNA markers, clinically feasible assays will be developed and their robustness tested in prospective studies.

P50 GM015431 (Morrow) 07/03/06 – 06/30/11
NIGMS Role: Co-Investigator
Research Center for Pharmacology and Drug Toxicology
The focus of the Center is research related to eicosanoid biology and pharmacology

R21 CA099269 (Berlin) 09/18/03 – 08/31/05
NCI Role: Co-Investigator
PS-341 in Hepatocellular Carcinoma: A Phase II Trial
Specific aims for this study are 1) Evaluate the antitumor effect of PS-341 in hepatocellular carcinoma patients, 2) Evaluate the effect of PS-341 on 26S proteasome activity in peripheral white blood cells (WBC's) and patient serum. Direct measurement of 26S proteasome activity as well as proteins affected by proteasome 26S and NF-kB will be analyzed, and 3) Evaluate the effect of PS-341 on intratumoral NF-kB activation, on tumor apoptosis and 26S proteasome activity.

R01 DK73902 (Peek) 04/01/06 – 12/31/10
NIDDKD Role: Co-Investigator
Mechanisms that Regulate Helicobacter Pylori-Induced Beta-Catenin Activation
The overarching objective of this program project is delineation of the molecular signaling events initiated by H. pylori:epithelial cell contact that regulate phenotypes related to gastric carcinogenesis.

P01 CA077839 (DuBois) 05/01/04 – 04/30/2009
NCI Role: Co-Investigator
Mechanisms for Chemoprevention of Cancer
The overall goal of this PPG is to determine the molecular mechanisms involved in the chemoprevention of cancer by non-steroidal anti-inflammatory drugs (NSAIDS). The studies will specifically test the hypotheses that the cyclooxygenase (COX) pathway and/or its eicosanoid products play a role in certain aspects of breast, cervical, ovarian and colorectal carcinogenesis.

P50 CA098131 (Moses) 09/25/06 – 07/31/11
NCI Role: Co-Investigator
HER (erbB) Inhibitors in Untreated Operable Breast Cancer (SPORE in Breast Cancer Supplement)
This supplement provides clinical trial, administrative, and correlative studies support for inter-SPORE clinical trials with the University of Alabama (Birmingham), University of North Carolina (Chapel Hill), and Dana-Farber Cancer Institute. The current trial targets 100 patients treated over the next 2 years with 1-2 weeks of the EGF receptor inhibitor erlotinib (OSI-774, 'Tarceva') in patients with operable breast cancer.

R01 CA080195 (Arteaga) 04/01/05 – 03/31/11
NCI Role: Co-Investigator
Erbb2-targeted anti-tumor strategies in breast cancer
The major goal of this project is to identify mechanisms of resistance to anti-HER2 drugs, contributing to the eventual elimination of HER2+ breast cancer.

R01 CA129961 (Moses) 04/01/08 – 03/31/12
NCI Role: Co-Investigator
Evaluation of MRI Biomarkers of Breast Cancer Response
The proposed research will combine several new imaging methods to obtain quantitative information on how breast tumors respond to treatment. We hypothesize that this will let us distinguish responders from non-responders early in the course of treatment.

STATISTICAL SOFTWARE

R, S-PLUS, SAS, MATLAB, Stata, SPSS, BDMP, SUDAAN, SOLAS, StaXact, Resampling Stats, East, nQuery Advisor, PASS, NCSS, StudySize, SYSTAT, GLIM, Minitab, EGRET, Epicure, PC Cluster, etc.

OPERATING SYSTEMS & LANGUAGES

LINUX, WINDOWS, DOS, UNIX, VAX/VMS, MAC, BASIC, FORTRAN, COBOL, C, C++, C-sharp, HTML, JAVA, etc.

INTERESTS

- Consulting on biomedical problems, designing experiments and data analysis, clinical trials design and analysis.
- Applied multivariate analysis, especially repeated measures procedures and high dimensional data analysis.
- Applied statistical methods in modern molecular biology: genomics and proteomics research.

BOOKS/BOOK CHAPTERS/BOOK REVIEWS

1. **Shyr Y** (2002). *Statistics with Applications to the Biomedical Science*. Tamkang Chair Lecture Series 132. Tamkang University, Taipei, Taiwan.
2. **Shyr Y** and Kim, KM (2003) *Weighted Flexible Compound Covariate Method for Classifying Microarray Data.* In: A Practical Approach to Microarray Data Analysis (Berrar, D., ed.), pp. 186-201, Kluwer Academic Publishers, Norwell, MA, USA.
3. **Shyr Y** (2006) *Statistical Approaches for High Dimensional Data Derived from High Throughput Assays*. In: Handbook of Statistics in Clinical Oncology 2nd edition (Crowley J, ed.), pp. 457-470, Chapman and Hall/CRC, Boca Raton, FL, USA.
4. Hong D and **Shyr Y** (2007) *Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques*, World Scientific Publication, Singapore, (ISBN: 978-981-270-461-0).
5. Hong D, Li HM, Li M, and **Shyr Y** (2007) *Evolution Algorithm and Recent Progress on Proteomic Data Preprocessing Using*. In: Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques, pp. 155-174. World Scientific Publication, Singapore.
6. Hong D, Yuan X, and **Shyr Y** (2007) *Survival Model and Estimation for Lung Cancer Patients*. In: Quantitative Medical Data Analysis Using Math Tools and Statistical Techniques, pp. 195-216. World Scientific Publication, Singapore.

7. Hong D and **Shyr Y** (2008) *Mathematical Framework and Wavelets Applications in Proteomics for Cancer Study*. In: Handbook of Cancer Models with Applications, (Wai-Yuan Tan and Leonid Hanin eds.), pp. 471-499, World Scientific, New Jersey, USA.

8. **Shyr Y** (2009) *Design and Conduct of Clinical Trials for Breast* Cancer. In: The Breast 4th ed - Comprehensive Management of Benign and Malignant Disorders. (Bland and Copeland, eds.), Elsevier, USA.

9. **Shyr Y** (2010) *Prediction of Antitumor Response.* In: Principles of Anticancer Drug Development 1st ed. (Hidalgo M, ed.), pp. 257-274. Springer, USA.

10. **Shyr Y**. Review of book: Design and Analysis of Clinical Trials with Time-to-Event Endpoint. *Biometrics* 2010; 66:659-660.

PUBLICATIONS

1. Baliga P, Merion RM, Turcotte JG, Ham JM, Henley KS, Lucey MR, Schork A, **Shyr Y**, Campbell DA, Jr. Preoperative risk factor assessment in liver transplantation. *Surgery* 1992;112(4):704-710; discussion 710-701.

2. Calkins H, **Shyr Y**, Schork A, Kadish A,Morady F. Effects of quinidine and amiodarone on blood pressure during rapid ventricular pacing in coronary artery disease. *Am J Cardiol* 1992;70(13):1206-1209.

3. Levy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Pagannelli F, Moyal C, Bremondy M, Schork A, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. *Circulation* 1992;86(5):1415-1420.

4. Wang HL, Burgett FG, **Shyr Y**. The relationship between restoration and furcation involvement on molar teeth. *Journal of Periodontology* 1993;64(4):302-305.

5. Wang HL, Yeh CT, Smith F, Burgett FG, Richards P, **Shyr Y**, O'Neal R. Evaluation of ferric oxalate as an agent for use during surgery to prevent post-operative root hypersensitivity. *Journal of Periodontology* 1993;64(11):1040-1044.

6. Wang HL, Burgett FG, **Shyr Y**, Ramfjord S. The influence of molar furcation involvement and mobility on future clinical periodontal attachment loss. *Journal of Periodontology* 1994;65(1):25-29.

7. Wang HL, O'Neal RB, Thomas CL, **Shyr Y**, MacNeil RL. Evaluation of an absorbable collagen membrane in treating Class II furcation defects. *Journal of Periodontology* 1994;65(11):1029-1036.

8. Wang HL, Pappert TD, Castelli WA, Chiego DJ, Jr., **Shyr Y**, Smith BA. The effect of platelet-derived growth factor on the cellular response of the periodontium: an autoradiographic study on dogs. *Journal of Periodontology* 1994;65(5):429-436.

9. Wang HL, Yuan K, Burgett F, **Shyr Y**, Syed S. Adherence of oral microorganisms to guided tissue membranes: an in vitro study. *Journal of Periodontology* 1994;65(3):211-218.

10. Young PC, **Shyr Y**, Schork MA. The role of the primary care physician in the care of children with serious heart disease. *Pediatrics* 1994;94(3):284-290.

11. Calkins H, **Shyr Y**, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. *American Journal of Medicine* 1995;98(4):365-373.

12. Chen CC, Wang HL, Smith F, Glickman GN, **Shyr Y**, O'Neal RB. Evaluation of a collagen membrane with and without bone grafts in treating periodontal intrabony defects. *Journal of Periodontology* 1995;66(10):838-847.

13. Herman GE, Schork MA, **Shyr Y**, Elfont EA, Arbit S. Histologists, Microtomy, Chronic Repetitive Trauma, and Techniques to Avoid Injury .1. A Statistical Evaluation of the Job Functions Performed by Histologists. *Journal of Histotechnology* 1995;18(2):139-143.

14. Loder RT, Farley FA, Herring JA, Schork MA, **Shyr Y**. Bone age determination in children with Legg-Calve-Perthes disease: a comparison of two methods. *Journal of Pediatric Orthopaedics* 1995;15(1):90-94.

15. Loder RT, Urquhart A, Steen H, Graziano G, Hensinger RN, Schlesinger A, Schork MA, **Shyr Y**. Variability in Cobb angle measurements in children with congenital scoliosis. *Journal of Bone and Joint Surgery (British Volume)* 1995;77(5):768-770.

16. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, **Shyr Y**, Strauss WE, Oates JA, Roberts LJ, 2nd. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. *New England Journal of Medicine* 1995;332(18):1198-1203.

17. Vrlenich LA, Bozynski ME, **Shyr Y**, Schork MA, Roloff DW, McCormick MC. The effect of bronchopulmonary dysplasia on growth at school age. *Pediatrics* 1995;95(6):855-859.

18. Calkins H, Bahu M, **Shyr Y**, Schork A, Bolling S, Kou W, Kirsch M, Morady F. Relationship of amiodarone to postoperative complications of transthoracic implantation of automatic implantable cardioverter defibrillators. *Panminerva Medica* 1996;38(2):89-97.

19. Chomsky DB, Lang CC, Rayos GH, **Shyr Y**, Yeoh TK, Pierson RN, 3rd, Davis SF, Wilson JR. Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. *Circulation* 1996;94(12):3176-3183.

20. Darbar D, Davidson NC, Gillespie N, Choy AM, Lang CC, **Shyr Y**, McNeill GP, Pringle TH, Struthers AD. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. *American Journal of Cardiology* 1996;78(3):284-287.

21. Johnson DH, Paul DM, Hande KR, **Shyr Y**, Blanke C, Murphy B, Lewis M, De Vore RF, 3rd. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. *Journal of Clinical Oncology* 1996;14(7):2054-2060.

22. Malicky DM, Soslowsky LJ, Blasier RB, **Shyr Y**. Anterior glenohumeral stabilization factors: progressive effects in a biomechanical model. *Journal of Orthopaedic Research* 1996;14(2):282-288.

23. Norris AE, Ford K, **Shyr Y**, Schork MA. Heterosexual experiences and partnerships of urban, low-income African-American and Hispanic youth. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1996;11(3):288-300.

24. Zic JA, Stricklin GP, Greer JP, Kinney MC, **Shyr Y**, Wilson DC, King LE, Jr. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. *Journal of the American Academy of Dermatology* 1996;35(6):935-945.

25. Blanke C, DeVore R, **Shyr Y**, Epstein B, Murray M, Hande K, Stewart S, Johnson D. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer. *International Journal of Radiation Oncology Biology Physics* 1997;37(1):111-116.

26. Chinery R, Brockman JA, Peeler MO, **Shyr Y**, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBP beta. *Nature Medicine* 1997;3(11):1233-1241.

27. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, **Shyr Y**, LaPorte K, Johnson DH. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. *Seminars in Oncology* 1997;24(4):21-26.

28. Coomer RW, Schulman G, Breyer JA, **Shyr Y**. Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. *American Journal of Kidney Diseases* 1997;29(5):678-684.

29. Goral S, Ynares C, **Shyr Y**, Yeoh TK, Johnson HK. Long-term renal function in heart transplant recipients receiving cyclosporine therapy. *Journal of Heart and Lung Transplantation* 1997;16(11):1106-1112.

30. Kemp WE, Jr., Kerins DM, **Shyr Y**, Byrd BF, 3rd. Optimal Albunex dosing for enhancement of Doppler tricuspid regurgitation spectra. *American Journal of Cardiology* 1997;79(2):232-234.

31. May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, HernanzSchulman M, **Shyr Y**, Hakim RM. Predictive measures of vascular access thrombosis: A prospective study. *Kidney International* 1997;52(6):1656-1662.

32. Metts JC, 3rd, Kotkin L, Kasper S, **Shyr Y**, Adams MC, Brock JW, 3rd. Genital malformations and coexistent urinary tract or spinal anomalies in patients with imperforate anus. *Journal of Urology* 1997;158(3 Pt 2):1298-1300.

33. Nicholson B, Paul D, **Shyr Y**, Garrett M, Hande KR, Johnson DH. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: A Vanderbilt cancer center phase II trial. *Seminars in Oncology* 1997;24(4):20-23.

34. **Shyr Y**, Kshirsagar AM. A formula for a missing plot in a general incomplete block design, when recovery of interblock information is used. *Communications in Statistics-Theory and Methods* 1997;26(12):2855-2860.

35. **Shyr Y**, Kshirsagar AM. Stepwise canonical analysis in categorical data. *Communications in Statistics-Theory and Methods* 1997;26(7):1575-1583.

36. Venkov CD, Su M, **Shyr Y**, Vaughan DE. Ethanol-induced alterations in the expression of endothelial-derived fibrinolytic components. *Fibrinolysis & Proteolysis* 1997;11(2):115-118.

37. Wang HL, MacNeil RL, Thomas C, **Shyr Y**, Syed S. The effect of an absorbable collagen membrane on the subgingival microflora. *Periodontal Clinical Investigations* 1997;19(1):27-35.

38. Chinery R, Beauchamp RD, **Shyr Y**, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. *Cancer Research* 1998;58(11):2323-2327.

39. Cowen ME, Dusseau DJ, Toth BG, Guisinger C, Zodet MW, **Shyr Y**. Casemix adjustment of managed care claims data using the Clinical Classification for Health Policy Research method. *Medical Care* 1998;36(7):1108-1113.

40. Evanson JA, Himmelfarb J, Wingard R, Knights S, **Shyr Y**, Schulman G, Ikizler TA, Hakim RM. Prescribed versus delivered dialysis in acute renal failure patients. *American Journal of Kidney Diseases* 1998;32(5):731-738.

41. Fitzpatrick JM, Hill DLG, **Shyr Y**, West J, Studholme C, Maurer CR. Visual assessment of the accuracy of retrospective registration of MR and CT images of the brain. *IEEE Transactions on Medical Imaging* 1998;17(4):571-585.

42. Lamps LW, Pinson CW, Raiford DS, **Shyr Y**, Scott MA, Washington MK. The significance of microabscesses in liver transplant biopsies: A clinicopathological study. *Hepatology* 1998;28(6):1532-1537.

43. Neyra NR, Ikizler TA, May RE, Himmelfarb J, Schulman G, **Shyr Y**, Hakim RM. Change in access blood flow over time predicts vascular access thrombosis. *Kidney International* 1998;54(5):1714-1719.

44. Ong MMA, Eber RM, Korsnes MI, MacNeil RL, Glickman GN, **Shyr Y**, Wang HL. Evaluation of a bioactive glass alloplast in treating periodontal intrabony defects. *Journal of Periodontology* 1998;69(12):1346-1354.

45. **Shyr Y**. Applied biostatistical method and models for survival analysis. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:24-27.

46. **Shyr Y**. Applying understanding and not misusing medical biostatistics. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:24-25.

47. **Shyr Y**. A canonical form of Anderson's classification statistic. *Communications in Statistics-Theory and Methods* 1998;27(3):577-587.

48. **Shyr Y**. The limitations and extensions of Cox model. *Medical Newsletter of Chang Gung Memorial Hospital (Taiwan)* 1998;8:26-28.

49. Washington K, Chiappori A, Hamilton K, **Shyr Y**, Blanke C, Johnson D, Sawyers J, Beauchamp D. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. *Modern Pathology* 1998;11(9):805-813.

50. Wolinsky PR, Banit D, Parker RE, **Shyr Y**, Snapper JR, Rutherford EJ, Johnson KD. Reamed intramedullary femoral nailing after induction of an "ARDS-like" state in sheep: Effect on clinically applicable markers of pulmonary function. *Journal of Orthopaedic Trauma* 1998;12(3):169-175.

51. Wolinsky PR, McCarty EC, **Shyr Y**, Johnson KD. Length of operative procedures: reamed femoral intramedullary nailing performed with and without a fracture table. *Journal of Orthopaedic Trauma* 1998;12(7):485-495.

52. Becker BN, Coomer RW, Fotiadis C, Evanson J, **Shyr Y**, Hakim RM. Risk factors for hospitalization in well-dialyzed chronic hemodialysis patients. *American Journal of Nephrology* 1999;19(5):565-570.

53. Chang AC, **Shyr Y**, Groves J, Chomsky DB, Davis SF, Wilson JR, Drinkwater DC, Pierson RN, Merrill WH. The utility of exercise testing after cardiac transplantation in older patients. *Journal of Surgical Research* 1999;81(1):48-54.

54. Choy H, LaPorte K, Knill-Selby E, Mohr P, **Shyr Y**. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. *Seminars in Radiation Oncology* 1999;9(2):90-96.

55. Cmelak AJ, Choy H, **Shyr Y**, Mohr P, Glantz MJ, Johnson DH. National survey on prophylactic cranial irradiation: Differences in practice patterns between medical and radiation oncologists. *International Journal of Radiation Oncology Biology Physics* 1999;44(1):157-162.

56. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, **Shyr Y**, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. *Journal of Nuclear Medicine* 1999;40(11):1784-1791.

57. Evanson JA, Ikizler TA, Wingard R, Knights S, **Shyr Y**, Schulman G, Himmelfarb J, Hakim RM. Measurement of the delivery of dialysis in acute renal failure. *Kidney International* 1999;55(4):1501-1508.

58. Herline AJ, Pinson CW, Wright JK, Debelak J, **Shyr Y**, Harley D, Merrill W, Starkey T, Pierson R, Chapman WC. Acute pancreatitis after cardiac transplantation and other cardiac procedures: Case-control analysis in 24,631 patients. *American Surgeon* 1999;65(9):819-825.

59. Hohenfellner K, Hunley TE, Brezinska R, Brodhag P, **Shyr Y**, Brenner W, Habermehl P, Kon V. ACE I/D gene polymorphism predicts renal damage in congenital uropathies. *Pediatric Nephrology* 1999;13(6):514-518.

60. Holcomb GW, Morgan WM, Neblett WW, Pietsch JB, O'Neill JA, **Shyr Y**. Laparoscopic cholecystectomy in children: Lessons learned from the first 100 patients. *Journal of Pediatric Surgery* 1999;34(8):1236-1240.

61. Hughes CA, O'Gorman LA, **Shyr Y**, Schork MA, Bozynski MEA, McCormick MC. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. *Journal of Developmental and Behavioral Pediatrics* 1999;20(1):1-8.

62. Ikizler TA, Wingard RL, Harvell J, **Shyr Y**, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. *Kidney International* 1999;55(5):1945-1951.

63. Lowe LH, Banks WJ, **Shyr Y**. Pyloric ratio: Efficacy in the diagnosis of hypertrophic pyloric stenosis. *Journal of Ultrasound in Medicine* 1999;18(11):773-777.

64. Norgaard P, Law B, Joseph H, Page DL, **Shyr Y**, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. *Clinical Cancer Research* 1999;5(1):35-42.

65. Rehman SU, Pupim LB, **Shyr Y**, Hakim R, Ikizler TA. Intradialytic serial vascular access flow measurements. *American Journal of Kidney Diseases* 1999;34(3):471-477.

66. **Shyr Y**. Statistical strategies for modeling the quasi-sinusoidality of time-qualified data. *Statistical Modeling* 1999;14:664-668.

67. Wolinsky PR, McCarty E, **Shyr Y**, Johnson K. Reamed intramedullary nailing of the femur: 551 cases. *Journal of Trauma-Injury Infection and Critical Care* 1999;46(3):392-399.

68. Zhang JP, Blum MG, Chang AC, **Shyr Y**, Blair KSA, Awwad M, Pierson RN. Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and anti-Gal column immune adsorption. *Xenotransplantation* 1999;6(4):249-261.

69. Chakravarthy A, Nicholson B, Kelley M, Beauchamp D, Johnson D, Frexes-Steed M, Simpson J, **Shyr Y**, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. *Clinical Breast Cancer* 2000;1(1):68-71.

70. Choy H, Devore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, **Shyr Y**, Johnson DH. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (A Vanderbilt cancer center affiliate network study). *International Journal of Radiation Oncology Biology Physics* 2000;47(4):931-937.

71. Choy H, **Shyr Y**, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for nonsmall cell lung carcinoma in the US. *Cancer* 2000;88(6):1336-1346.

72. Franke JJ, Gilbert WB, Grier J, Koch MO, **Shyr Y**, Smith JA. Early post-prostatectomy pelvic floor biofeedback. *Journal of Urology* 2000;163(1):191-193.

73. Hernanz-Schulman M, Foster C, Maxa R, Battles G, Dutt P, Stratton C, Holburn G, Schulman G, Neblett WW, **Shyr Y**, Hakim RR, Vanholder R, Heller RM. Experimental study of mortality and morbidity of contrast media and standardized fecal dose in the peritoneal cavity. *Pediatric Radiology* 2000;30(6):369-378.

74. Komhoff M, Guan YF, Shappell HW, Davis L, Jack G, **Shyr Y**, Koch MO, Shappell SB, Breyer MD. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. *American Journal of Pathology* 2000;157(1):29-35.

75. Lowe LH, Penney MW, Scheker LE, Perez R, Stein SM, Heller RM, **Shyr Y**, Hernanz-Schulman M. Appendicolith revealed on CT in children with suspected appendicitis: How specific is it in the diagnosis of appendicitis? *American Journal of Roentgenology* 2000;175(4):981-984.

76. Mertz H, Morgan V, Tanner G, Pickens D, Price R, **Shyr Y**, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. *Gastroenterology* 2000;118(5):842-848.

77. Mizobata S, Tompkins K, Simpson JF, **Shyr Y**, Primus FJ. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. *Cancer Immunology Immunotherapy* 2000;49(6):285-295.

78. Neyra NR, Hakim RM, **Shyr Y**, Ikizler TA. Serum transferrin and serum prealbumin are early predictors of serum albumin in chronic hemodialysis patients. *Journal of Renal Nutrition* 2000;10(4):184-190.

79. Nicholson BP, Paul DM, Hande KR, **Shyr Y**, Meshad M, Cohen A, Johnson DH. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. *Clinical Breast Cancer* 2000;1(2):136-143; discussion 144.

80. Roberts JR, **Shyr Y**, Christian KR, Drinkwater D, Merrill W. Preemptive gastrointestinal tract management reduces aspiration and respiratory failure after thoracic operations. *Journal of Thoracic and Cardiovascular Surgery* 2000;119(3):449-452.

81. **Shyr Y**. The current challenges and future of bioinformatics. *Proceeding of Taiwan Biotechnology Symposiums* 2000:15-22.

82. **Shyr Y**. The statistical strategies for modeling the relationship between multiple variable and RNA expression data adn clinical endpoints. *Proceeding of Taiwan Biotechnology Symposiums* 2000:1-14.

83. Stefansic JD, Herline AJ, **Shyr Y**, Chapman WC, Fitzpatrick JM, Dawant BM, Galloway RL. Registration of physical space to laparoscopic image space for use in minimally invasive hepatic surgery. *IEEE Transactions on Medical Imaging* 2000;19(10):1012-1023.

84. Tingstad EM, Wolinsky PR, **Shyr Y**, Johnson KD. Effect of immediate weightbearing on plated fractures of the humeral shaft. *Journal of Trauma-Injury Infection and Critical Care* 2000;49(2):278-280.

85. Washington K, Wright K, **Shyr Y**, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. *Human Pathology* 2000;31(7):822-828.

86. Xu XC, Clarke P, Szalai G, Shively JE, Williams LE, **Shyr Y**, Shi EG, Primus FJ. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. *Cancer Research* 2000;60(16):4475-4484.

87. Amorino GP, Lee H, Holburn GE, Paschal CB, Hercules SK, **Shyr Y**, Steffen RP, Choy H. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. *Radiation Research* 2001;156(3):294-300.

88. Blanke CD, Stipanov M, Morrow J, Rothenberg M, Chinery R, **Shyr Y**, Coffey R, Johnson DH, Leach SD, Beauchamp RD. A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. *Investigational New Drugs* 2001;19(1):21-27.

89. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, Laporte K, **Shyr Y**, Johnson DH. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. *Lung Cancer* 2001;34(3):441-449.

90. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, **Shyr Y**, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. *Cancer Research* 2001;61(14):5389-5395.

91. Dowell JE, Garrett AM, **Shyr Y**, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. *Cancer* 2001;91(3):592-597.

92. Dowell JE, Johnson DH, Rogers JS, **Shyr Y**, McCullough N, Krozely P, DeVore RF. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. *Investigational New Drugs* 2001;19(1):85-88.

93. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, **Shyr Y**, Carbone DP, DeVore RF. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study. *Clinical Cancer Research* 2001;7(1):68-73.

94. Lowe LH, Penney MW, Stein SM, Heller RM, Neblett WW, **Shyr Y**, Hernanz-Schulman M. Unenhanced limited CT of the abdomen in the diagnosis of appendicitis in children: Comparison with sonography. *American Journal of Roentgenology* 2001;176(1):31-35.

95. McCarley P, Wingard RL, **Shyr Y**, Pettus W, Hakim RM, Ikizler TA. Vascular access blood flow monitoring reduces access morbidity and costs. *Kidney International* 2001;60(3):1164-1172.

96. McCarty EC, Spindler KP, Tingstad E, **Shyr Y**, Higgins M. Does intraarticular morphine improve pain control with femoral nerve block after anterior cruciate ligament reconstruction? *American Journal of Sports Medicine* 2001;29(3):327-332.

97. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, **Shyr Y**, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. *Human Pathology* 2001;32(4):368-378.

98. Murphy BA, Cmelak A, Burkey B, Netterville J, **Shyr Y**, Douglas S, Smith W. Topoisomerase I inhibitors in the treatment of head and neck cancer. *Oncology (Williston Park)* 2001;15(7 Suppl 8):47-52.

99. Pietrow PK, Parekh DJ, Smith JA, Jr., **Shyr Y**, Cookson MS. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. *Journal of Urology* 2001;166(6):2286-2290.

100. Saadeh E, Ikizler TA, **Shyr Y**, Hakim RM, Himmelfarb J. Recombinant human growth hormone in patients with acute renal failure. *Journal of Renal Nutrition* 2001;11(4):212-219.

101. Sofowora GG, Choo EF, Mayo G, **Shyr Y**, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. *Cancer Chemotherapy and Pharmacology* 2001;47(6):505-510.

102. Tham KT, Peek RM, Atherton JC, Cover TL, Perez-Perez GI, **Shyr Y**, Blaser MJ. Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. *Human Pathology* 2001;32(3):264-273.

103. Wang HL, Bunyaratavej P, Labadie M, **Shyr Y**, MacNeil RL. Comparison of 2 clinical techniques for treatment of gingival recession. *Journal of Periodontology* 2001;72(10):1301-1311.

104. Washington K, Debelak JP, Gobbell C, Sztipanovits DR, **Shyr Y**, Olson S, Chapman WC. Hepatic cryoablation-induced acute lung injury: Histopathologic findings. *Journal of Surgical Research* 2001;95(1):1-7.

105. Boyd AS, **Shyr Y**, King LE, Jr. Basal cell carcinoma in young women: an evaluation of the association of tanning bed use and smoking. *Journal of the American Academy of Dermatology* 2002;46(5):706-709.

106. Caglar K, Fedje L, Dimmitt R, Hakim RM, **Shyr Y**, Ikizler TA. Therapeutic effects of oral nutritional supplementation during hemodialysis. *Kidney International* 2002;62(3):1054-1059.

107. Chen S-Y, Wang H-L, Glickman GN, **Shyr Y**, MacNeil RL. Multivariate analysis of factors influencing outcomes of regenerative therapy: a retrospective study. *International Chinese Journal of Dentistry* 2002;2:50-59.

108. Hallahan DE, Geng L, **Shyr Y**. Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. *Journal of the National Cancer Institute* 2002;94(10):733-741.

109. Himmelfarb J, Evanson J, Hakim RM, Freedman S, **Shyr Y**, Ikizler TA. Urea volume of distribution exceeds total body water in patients with acute renal failure. *Kidney International* 2002;61(1):317-323.

110. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, **Shyr Y**, Himmelfarb J. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. *Clinical Nephrology* 2002;58(3):190-197.

111. Miller MF, McDowell T, Small SE, **Shyr Y**, Kemp NR. Hardly used habitats: Dearth and distribution of burrowing in Paleozoic and Mesozoic stream and lake deposits. *Geology* 2002;30(6):527-530.

112. Pietrow PK, Pope JCt, Adams MC, **Shyr Y**, Brock JW, 3rd. Clinical outcome of pediatric stone disease. *Journal of Urology* 2002;167(2 Pt 1):670-673.

113. Pupim LB, Kent P, Caglar K, **Shyr Y**, Hakim RM, Ikizler TA. Improvement in nutritional parameters after initiation of chronic hemodialysis. *American Journal of Kidney Diseases* 2002;40(1):143-151.

114. Washington K, Greenson JK, Montgomery E, **Shyr Y**, Crissinger KD, Polk DB, Barnard J, Lauwers GY. Histopathology of ulcerative colitis in initial rectal biopsy in children. *American Journal of Surgical Pathology* 2002;26(11):1441-1449.

115. Wudel LJ, Jr., Chapman WC, **Shyr Y**, Davidson M, Jeyakumar A, Rogers SO, Jr., Allos T, Stain SC. Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival. *Archives of Surgery* 2002;137(5):550-554; discussion 554-556.

116. Wudel LJ, Jr., Wright JK, Debelak JP, Allos TM, **Shyr Y**, Chapman WC. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. *Journal of Surgical Research* 2002;102(1):50-56.

117. Gorska AE, Jensen RA, **Shyr Y**, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. *American Journal of Pathology* 2003;163(4):1539-1549. PMCID: PMC1868288.

118. Kim JC, Kim JS, Saha D, Cao Q, **Shyr Y**, Choy H. Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. *Radiotherapy and Oncology* 2003;68(3):305-313.

119. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, **Shyr Y**, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. *Cancer Research* 2003;63(21):7113-7121.

120. Neyra R, Chen KY, Sun M, **Shyr Y**, Hakim RM, Ikizler TA. Increased resting energy expenditure in patients with end-stage renal disease. *Journal of Parenteral and Enteral Nutrition* 2003;27(1):36-42.

121. **Shyr Y**. Statistical strategies for analyzing the microarray data in human lung cancer. *Lung Cancer* 2003;41(2003):90-91.

122. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, **Shyr Y**, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ. The loss of TGF-beta signaling promotes prostate cancer metastasis. *Neoplasia* 2003;5(3):267-277. PMCID: PMC1502411.

123. VanderVeen LA, Hashim MF, **Shyr Y**, Marnett LJ. Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100(24):14247-14252. PMCID: PMC283577.

124. Wudel LJ, Jr., Delbeke D, Morris D, Rice M, Washington MK, **Shyr Y**, Pinson CW, Chapman WC. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. *American Surgeon* 2003;69(2):117-124; discussion 124-116.

125. Xie L, Law BK, Aakre ME, Edgerton M, **Shyr Y**, Bhowmick NA, Moses HL. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. *Breast Cancer Res* 2003;5(6):R187-198. PMCID: PMC314403.

126. Yamagata N, **Shyr Y**, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, Nadaf S, Larsen P, Roberts JR, Nesbitt JC, Jensen R, Levy S, Moore JH, Minna JD, Carbone DP. A training-testing approach to the molecular classification of resected non-small cell lung cancer. *Clinical Cancer Research* 2003;9(13):4695-4704.

127. Yanagisawa K, **Shyr Y**, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. Proteomic patterns of tumour subsets in non-small-cell lung cancer. *Lancet* 2003;362(9382):433-439.

128. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, **Shyr Y**, Boothby M, Joyce S, Carbone DP, Breyer RM. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. *Journal of Clinical Investigation* 2003;111(5):727-735. PMCID: PMC151895.

129. Gonzalez AL, Roberts RL, Massion PP, Olson SJ, **Shyr Y**, Shappell SB. 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation. *Human Pathology* 2004;35(7):840-849.

130. Ikizler TA, Sezer MT, Flakoll PJ, Hariachar S, Kanagasundaram NS, Gritter N, Knights S, **Shyr Y**, Paganini E, Hakim RM, Himmelfarb J. Urea space and total body water measurements by stable isotopes in patients with acute renal failure. *Kidney International* 2004;65(2):725-732.

131. Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, **Shyr Y**, Stein R, Zic J, Greer J. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. *Leukemia & Lymphoma* 2004;45(11):2261-2267.

132. Jennings MT, Cmelak A, Johnson MD, Moots PL, Pais R, **Shyr Y**. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. *Pediatric Blood & Cancer* 2004;43(1):46-54.

133. Kimble KM, Eber RM, Soehren S, **Shyr Y**, Wang HL. Treatment of gingival recession using a collagen membrane with or without the use of demineralized freeze-dried bone allograft for space maintenance. *Journal of Periodontology* 2004;75(2):210-220.

134. Lu B, Gonzalez A, Massion PP, **Shyr Y**, Shaktour B, Carbone DP, Hallahan DE. Nuclear survivin as a biomarker for non-small-cell lung cancer. *British Journal of Cancer* 2004;91(3):537-540. PMCID: PMC2409840.

135. Massion PP, Taflan PM, **Shyr Y**, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. *American Journal of Respiratory and Critical Care Medicine* 2004;170(10):1088-1094.

136. Osusky KL, Hallahan DE, Fu A, Ye F, **Shyr Y**, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. *Angiogenesis* 2004;7(3):225-233.

137. Pupim LB, Caglar K, Hakim RM, **Shyr Y**, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. *Kidney International* 2004;66(5):2054-2060.

138. Pupim LB, Himmelfarb J, McMonagle E, **Shyr Y**, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. *Kidney International* 2004;65(6):2371-2379.

139. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, **Shyr Y**, Ikizler TA. Plasma cytokine levels predict mortality in patients with acute renal failure. *Kidney International* 2004;65(4):1357-1365.

140. Tedesco KL, Thor AD, Johnson DH, **Shyr Y**, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW, Jr. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. *Journal of Clinical Oncology* 2004;22(6):1071-1077.

141. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, **Shyr Y**, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell* 2004;6(4):409-421.

142. Basi S, Pupim LB, Simmons EM, Sezer MT, **Shyr Y**, Freedman S, Chertow GM, Mehta RL, Paganini E, Himmelfarb J, Ikizler TA. Insulin resistance in critically ill patients with acute renal failure. *American Journal of Physiology - Renal Physiology* 2005;289(2):F259-264.

143. Boyd AS, Wu H, **Shyr Y**. Monster cells in malignant melanoma. *American Journal of Dermatopathology* 2005;27(3):208-210.

144. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, **Shyr Y**, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. *FASEB Journal* 2005;19(13):1884-1886.

145. Bui CM, Chen H, **Shyr Y**, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. *J Allergy Clin Immunol* 2005;116(5):1042-1047.

146. Csiki I, Morrow JD, Sandler A, **Shyr Y**, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. *Clinical Cancer Research* 2005;11(18):6634-6640.

147. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, **Shyr Y**, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. *Circulation Research* 2005;97(5):496-504.

148. Grau AM, Ata A, Foster L, Ahmed NU, Gorman DR, **Shyr Y**, Stain SC, Pearson AS. Effect of race on long-term survival of breast cancer patients: transinstitutional analysis from an inner city hospital and university medical center. *American Surgeon* 2005;71(2):164-170.

149. Kim DW, **Shyr Y**, Chen H, Akerley W, Johnson DH, Choy H. Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics* 2005;63(4):1029-1036.

150. Kim DW, **Shyr Y**, Shaktour B, Akerley W, Johnson DH, Choy H. Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. *Lung Cancer* 2005;50(2):235-245.

151. Kuhn JE, Huston LJ, Soslowsky LJ, **Shyr Y**, Blasier RB. External rotation of the glenohumeral joint: ligament restraints and muscle effects in the neutral and abducted positions. *Journal of Shoulder and Elbow Surgery* 2005;14(1 Suppl S):39S-48S.

152. Maas K, Chen H, **Shyr Y**, Olsen NJ, Aune T. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. *Human Molecular Genetics* 2005;14(10):1305-1314.

153. Park YK, Franklin JL, Settle SH, Levy SE, Chung E, Jeyakumar LH, **Shyr Y**, Washington MK, Whitehead RH, Aronow BJ, Coffey RJ. Gene expression profile analysis of mouse colon embryonic development. *Genesis* 2005;41(1):1-12.

154. Rahman SM, **Shyr Y**, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, Ninan M, Miller YE, Franklin WA, Caprioli RM, Carbone DP, Massion PP. Proteomic patterns of preinvasive bronchial lesions. *American Journal of Respiratory and Critical Care Medicine* 2005;172(12):1556-1562. PMCID: PMC2718455.

155. Schwartz SA, Weil RJ, Thompson RC, **Shyr Y**, Moore JH, Toms SA, Johnson MD, Caprioli RM. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. *Cancer Research* 2005;65(17):7674-7681.

156. Shinohara ET, Geng L, Tan J, Chen H, **Shyr Y**, Edwards E, Halbrook J, Kesicki EA, Kashishian A, Hallahan DE. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation sensitizing drugs. *Cancer Research* 2005;65(12):4987-4992.

157. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, **Shyr Y**, Carbone DP, Johnson DH, Hallahan DE, Lu B. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. *Cancer* 2005;103(8):1685-1692.

158. Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, **Shyr Y**, Caillouette C, Chakravarthy B. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. *International Journal of Radiation Oncology Biology Physics* 2005;61(5):1364-1370.

159. Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, **Shyr Y**, Caillouette C, Chakravarthy B. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. *Radiotherapy and Oncology* 2005;76(1):54-58.

160. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S, Brandt SJ, Roberts J, Zhang X, **Shyr Y**, Kinney MC. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. *Human Pathology* 2005;36(5):494-504.

161. Xie L, Xu BJ, Gorska AE, **Shyr Y**, Schwartz SA, Cheng N, Levy S, Bierie B, Caprioli RM, Moses HL. Genomic and proteomic analysis of mammary tumors arising in transgenic mice. *Journal of Proteome Research* 2005;4(6):2088-2098.

162. Xu BJ, **Shyr Y**, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. *Journal of the American Society of Nephrology* 2005;16(10):2967-2975.

163. Yi Y, Mirosevich J, **Shyr Y**, Matusik R, George AL, Jr. Coupled analysis of gene expression and chromosomal location. *Genomics* 2005;85(3):401-412.

164. Baker SG, Kramer BS, McIntosh M, Patterson BH, **Shyr Y**, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. *Clinical Trials* 2006;3(1):43-56.

165. Cuneo KC, Geng L, Tan J, Brousal J, Shinohara ET, Osusky K, Fu A, **Shyr Y**, Wu H, Hallahan DE. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. *International Journal of Radiation Oncology Biology Physics* 2006;64(4):1197-1203.

166. Dennehy MK, Richards KA, Wernke GR, **Shyr Y**, Liebler DC. Cytosolic and nuclear protein targets of thiol-reactive electrophiles. *Chemical Research in Toxicology* 2006;19(1):20-29.

167. Geng L, Shinohara ET, Kim D, Tan J, Osusky K, **Shyr Y**, Hallahan DE. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. *International Journal of Radiation Oncology Biology Physics* 2006;64(1):263-271.

168. Hong D, **Shyr Y**. Wavelets in biostatistics. *Journal of Concrete and Applicable Mathematics* 2006;4:505-521.

169. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, **Shyr Y**, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. *PLoS Med* 2006;3(12):e486. PMCID: PMC1716188.

170. Slebos RJ, Li M, Evjen AN, Coffa J, **Shyr Y**, Yarbrough WG. Mutagenic effect of cadmium on tetranucleotide repeats in human cells. *Mutation Research* 2006;602(1-2):92-99.

171. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, **Shyr Y**, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. *Clinical Cancer Research* 2006;12(3 Pt 1):701-709.

172. Wetzel JD, Barton ES, Chappell JD, Baer GS, Mochow-Grundy M, Rodgers SE, **Shyr Y**, Powers AC, Thomas JW, Dermody TS. Reovirus delays diabetes onset but does not prevent insulitis in nonobese diabetic mice. *Journal of Virology* 2006;80(6):3078-3082. PMCID: PMC1395416.

173. Wright RW, Boyce RH, Michener T, **Shyr Y**, McCarty EC, Spindler KP. Radiographs are not useful in detecting arthroscopically confirmed mild chondral damage. *Clinical Orthopaedics and Related Research* 2006;442:245-251.

174. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, **Shyr Y**, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. *Journal of Clinical Oncology* 2007;25(16):2184-2190.

175. Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, **Shyr Y**, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB, Jr., Johnson DH, Lu B. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. *Cancer Epidemiology Biomarkers & Prevention* 2007;16(9):1845-1851.

176. Chen S, Hong D, **Shyr Y**. Wavelet-based procedures for proteomic mass spectrometry data processing. *Computational Statistics & Data Analysis* 2007;52(1):211-220.

177. Cheng N, Chytil A, **Shyr Y**, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. *Cancer Research* 2007;67(10):4869-4877.

178. Cmelak AJ, Murphy BA, Burkey B, Douglas S, **Shyr Y**, Netterville J. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. *Head Neck* 2007;29(4):315-324.

179. Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Cai Q, Smalley WE, Li M, **Shyr Y**, Zheng W. The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. *American Journal of Clinical Nutrition* 2007;86(3):743-751. PMCID: PMC2082111.

180. Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, **Shyr Y**, Holt JT, Moses HL, Jensen RA. Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. *International Journal of Biological Sciences* 2007;3(5):281-291. PMCID: PMC1865089.

181. Jiang A, Pan W, Milbauer LC, **Shyr Y**, Hebbel RP. A practical question based on cross-platform microarray data normalization: are BOEC more like large vessel or microvascular endothelial cells or neither of them? *Journal of Bioinformatics and Computational Biology* 2007;5(4):875-893.

182. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, **Shyr Y**, Robbins JB. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. *Journal of Cutaneous Pathology* 2007;34(8):593-596. PMCID: PMC2665272.

183. Kim DW, Blanke CD, Wu H, **Shyr Y**, Berlin J, Beauchamp RD, Chakravarthy B. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. *International Journal of Radiation Oncology Biology Physics* 2007;67(2):397-404.

184. Li JQ, Xu BJ, Shakhtour B, Deane N, Merchant N, Heslin MJ, Washington K, Coffey RJ, Beauchamp RD, **Shyr Y**, Billheimer D. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. *International Journal of Oncology* 2007;31(1):103-111.

185. Lovvorn HN, 3rd, Boyle S, Shi G, **Shyr Y**, Wills ML, Perantoni AO, de Caestecker M. Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1. *Journal of Pediatric Surgery* 2007;42(3):474-481. PMCID: PMC3028602.

186. Murff HJ, Shrubsole MJ, Smalley WE, Wu H, **Shyr Y**, Ness RM, Zheng W. The interaction of age and hormone replacement therapy on colon adenoma risk. *Cancer Detection and Prevention* 2007;31(2):161-165. PMCID: PMC1949417.

187. Roberts LJ, 2nd, Oates JA, Linton MF, Fazio S, Meador BP, Gross MD, **Shyr Y**, Morrow JD. The relationship between dose of vitamin E and suppression of oxidative stress in humans. *Free Radical Biology & Medicine* 2007;43(10):1388-1393. PMCID: PMC2072864.

188. Shin A, Shrubsole MJ, Ness RM, Wu H, Sinha R, Smalley WE, **Shyr Y**, Zheng W. Meat and meat-mutagen intake, doneness preference and the risk of colorectal polyps: the Tennessee Colorectal Polyp Study. *International Journal of Cancer* 2007;121(1):136-142.

189. Shinohara ET, Gonzalez A, Massion PP, Olson SJ, Albert JM, **Shyr Y**, Carbone DP, Johnson DH, Hallahan DE, Lu B. PDGFR-beta expression in small cell lung cancer patients. *International Journal of Radiation Oncology Biology Physics* 2007;67(2):431-437.

190. Sinsakul M, Sika M, Rodby R, Middleton J, **Shyr Y**, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. *American Journal of Kidney Diseases* 2007;50(6):946-951.

191. Tang YW, Li H, Wu H, **Shyr Y**, Edwards KM. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine. *Journal of Infectious Diseases* 2007;196(7):1021-1025.

192. Wall RJ, **Shyr Y**, Smalley W. Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. *Journal of Thoracic Oncology* 2007;2(2):109-114.

193. Willey CD, Murphy BA, Netterville JL, Burkey BB, **Shyr Y**, Shakhtour B, Kish B, Raben D, Chen C, Song JI, Kane MA, Cmelak AJ. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. *International Journal of Radiation Oncology Biology Physics* 2007;67(5):1323-1331.

194. Woodhams DC, Vredenburg VT, Simon MA, Billheimer D, Shakhtour B, **Shyr Y**, Briggs CJ, Rollins-Smith LA, Harris RN. Symbiotic bacteria contribute to innate immune defenses of the threatened mountain yellow-legged frog, Rana muscosa. *Biological Conservation* 2007;138(3-4):390-398.

195. Wu H, Muscato NE, Gonzalez A, **Shyr Y**. An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study. *Biomark Insights* 2007;2:469-476. PMCID: PMC2717822.

196. Ye F, **Shyr Y**. Balanced two-stage designs for phase II clinical trials. *Clinical Trials* 2007;4(5):514-524.

197. Yildiz PB, **Shyr Y**, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. *Journal of Thoracic Oncology* 2007;2(10):893-901.

198. Boyd AS, Shakhtour B, **Shyr Y**. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. *Journal of the American Academy of Dermatology* 2008;58(5):750-754.

199. Cheng N, Chytil A, **Shyr Y**, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. *Molecular Cancer Research* 2008;6(10):1521-1533. PMCID: PMC2740918.

200. Frangoul H, Al-Jadiry MF, **Shyr Y**, Ye F, Shakhtour B, Al-Hadad SA. Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990-2002. *New England Journal of Medicine* 2008;359(4):435-437.

201. Gilbert J, Cmelak A, **Shyr Y**, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. *Cancer* 2008;113(1):186-192.

202. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, **Shyr Y**, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. *Journal of Clinical Oncology* 2008;26(6):897-906.

203. Harris EI, Lewin DN, Wang HL, Lauwers GY, Srivastava A, **Shyr Y**, Shakhtour B, Revetta F, Washington MK. Lymphovascular invasion in colorectal cancer: an interobserver variability study. *American Journal of Surgical Pathology* 2008;32(12):1816-1821. PMCID: PMC2605104.

204. Huang T, Tu K, **Shyr Y**, Wei CC, Xie L, Li YX. The prediction of interferon treatment effects based on time series microarray gene expression profiles. *Journal of Translational Medicine* 2008;6:44. PMCID: PMC2546378.

205. Lin KC, Chen YJ, **Shyr Y**. A nonparametric smoothing method for assessing GEE models with longitudinal binary data. *Statistics in Medicine* 2008;27(22):4428-4439.

206. Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, **Shyr Y**, Spitz MR. Smoking-related genomic signatures in non-small cell lung cancer. *American Journal of Respiratory and Critical Care Medicine* 2008;178(11):1164-1172. PMCID: PMC2720147.

207. Ni TT, Lemon WJ, **Shyr Y**, Zhong TP. Use of normalization methods for analysis of microarrays containing a high degree of gene effects. *BMC Bioinformatics* 2008;9:505. PMCID: PMC2612699.

208. Shin A, Shrubsole MJ, Rice JM, Cai Q, Doll MA, Long J, Smalley WE, **Shyr Y**, Sinha R, Ness RM, Hein DW, Zheng W. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. *Cancer Epidemiology Biomarkers & Prevention* 2008;17(2):320-329. PMCID: PMC2572782.

209. Shinall MC, Jr., Koehler E, **Shyr Y**, Lovvorn HN, 3rd. Comparing cost and complications of primary and staged surgical repair of neonatally diagnosed Hirschsprung's disease. *Journal of Pediatric Surgery* 2008;43(12):2220-2225.

210. Shrubsole MJ, Wu H, Ness RM, **Shyr Y**, Smalley WE, Zheng W. Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps. *American Journal of Epidemiology* 2008;167(9):1050-1058.

211. Slebos RJ, Li M, Vadivelu S, Burkey BB, Netterville JL, Sinard R, Gilbert J, Murphy B, Chung CH, **Shyr Y**, Yarbrough WG. Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. *British Journal of Cancer* 2008;98(3):619-626. PMCID: PMC2243146.

212. Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, **Shyr Y**, Carbone DP, Caprioli RM. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. *Proteomics – Clinical Applications* 2008;2(10-11):1508-1517.

213. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, **Shyr Y**, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. *Journal of Clinical Investigation* 2009;119(6):1571-1582. PMCID: PMC2689133.

214. Buzzell JE, Lutton DM, **Shyr Y**, Neviaser RJ, Lee DH. Reliability and accuracy of templating the proximal humeral component for shoulder arthroplasty. *Journal of Shoulder and Elbow Surgery* 2009;18(5):728-733.

215. Chen S, Li M, Hong D, Billheimer D, Li H, Xu BJ, **Shyr Y**. A novel comprehensive wave-form MS data processing method. *Bioinformatics* 2009;25(6):808-814. PMCID: PMC2732299.

216. Davies SS, Traustadottir T, Stock AA, Ye F, **Shyr Y**, Harman SM, Roberts LJ, 2nd. Ischemia/reperfusion unveils impaired capacity of older adults to restrain oxidative insult. *Free Radical Biology & Medicine* 2009;47(7):1014-1018. PMCID: PMC2748908.

217. Li S, Li H, Li M, **Shyr Y**, Xie L, Li Y. Improved prediction of lysine acetylation by support vector machines. *Protein and Peptide Letters* 2009;16(8):977-983.

218. Lovejoy CA, Xu X, Bansbach CE, Glick GG, Zhao R, Ye F, Sirbu BM, Titus LC, **Shyr Y**, Cortez D. Functional genomic screens identify CINP as a genome maintenance protein. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106(46):19304-19309. PMCID: PMC2780779.

219. Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Jr., Sandler AB, **Shyr Y**, Lu B. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. *The Oncologist* 2009;14(11):1106-1115. PMCID: PMC3045762.

220. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, **Shyr Y**, Ye F, Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. *Clinical Cancer Research* 2009;15(6):2158-2165.

221. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, **Shyr Y**, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. *Journal of Thoracic Oncology* 2009;4(6):689-696. PMCID: PMC3563261.

222. Tennessen JA, Woodhams DC, Chaurand P, Reinert LK, Billheimer D, **Shyr Y**, Caprioli RM, Blouin MS, Rollins-Smith LA. Variations in the expressed antimicrobial peptide repertoire of northern leopard frog (Rana pipiens) populations suggest intraspecies differences in resistance to pathogens. *Developmental and Comparative Immunology* 2009;33(12):1247-1257. PMCID: PMC2927990.

223. Wu H, Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Smalley WE, Chen H, Li M, **Shyr Y**, Zheng W. Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. *Journal of Nutrition* 2009;139(2):340-344. PMCID: PMC2646202.

224. Wu J, Qiu Q, Xie L, Fullerton J, Yu J, **Shyr Y**, George AL, Jr., Yi Y. Web-based interrogation of gene expression signatures using EXALT. *BMC Bioinformatics* 2009;10:420. PMCID: PMC2799423.

225. Wujcik D, **Shyr Y**, Li M, Clayton MF, Ellington L, Menon U, Mooney K. Delay in diagnostic testing after abnormal mammography in low-income women. *Oncology Nursing Forum* 2009;36(6):709-715.

226. Xu BJ, Li J, Beauchamp RD, **Shyr Y**, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. *Molecular & Cellular Proteomics* 2009;8(5):936-945. PMCID: PMC2689774.

227. Zhao BB, **Shyr Y**. Discrimination or differing model structures? Alternatives and extensions to Blinder-Oaxaca decomposition. *Journal of Economic and Social Measurement* 2009;34(2,3):159-174.

228. Barton CE, Johnson KN, Mays DM, Boehnke K, **Shyr Y**, Boukamp P, Pietenpol JA. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. *Cell Death & Disease* 2010;1(9):e74. PMCID: PMC3000738.

229. Chong PY, Koehler EA, **Shyr Y**, Watson JT, Weikert DR, Rowland JH, Lee DH. Driving with an arm immobilized in a splint: a randomized higher-order crossover trial. *Journal of Bone and Joint Surgery (American Volume)* 2010;92(13):2263-2269.

230. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, **Shyr Y**, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Annals of Oncology* 2010;21(4):864-870. PMCID: PMC2844946.

231. Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, **Shyr Y**, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics* 2010;77(2):468-476.

232. Grogan EL, Deppen S, Pecot CV, Putnam JB, Jr., Nesbitt JC, **Shyr Y**, Rajanbabu R, Ory B, Lambright ES, Massion PP. Diagnostic characteristics of a serum biomarker in patients with positron emission tomography scans. *The Annals of Thoracic Surgery* 2010;89(6):1724-1728; discussion 1728-1729. PMCID: PMC3026702.

233. Hassanein M, Weidow B, Koehler E, Bakane N, Garbett S, **Shyr Y**, Quaranta V. Development of High-Throughput Quantitative Assays for Glucose Uptake in Cancer Cell Lines. *Molecular Imaging and Biology* 2010.

234. Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, **Shyr Y**, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. *PLoS ONE* 2010;5(9):e12702. PMCID: PMC2938338.

235. Kobayashi H, Huang J, Ye F, **Shyr Y**, Blackwell TS, Lin PC. Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. *PLos ONE* 2010;5(3):e9458. PMCID: PMC2832764.

236. Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, **Shyr Y**, Slebos RJ. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. *Journal of Proteome Research* 2010;9(8):4295-4305. PMCID: PMC2920032.

237. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, **Shyr Y**, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. *Journal of Clinical Investigation* 2010;120(7):2406-2413. PMCID: PMC2898598.

238. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, **Shyr Y**, Estrada L, Quaranta V, Massion PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. *Oncogene* 2010;29(48):6331-6342.

239. Ogden SR, Noto JM, Allen SS, Patel DA, Romero-Gallo J, Washington MK, Fingleton B, Israel DA, Lewis ND, Wilson KT, Chaturvedi R, Zhao Z, **Shyr Y**, Peek RM, Jr. Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. *Cancer Research* 2010;70(1):30-35. PMCID: PMC2804939.

240. Perez CA, Chen H, **Shyr Y**, Courtney R, Zheng W, Cai Q, Hwang M, Jaboin J, Schleicher S, Moretti L, Wills M, Smith JA, Lu B. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. *Journal of Urology* 2010;183(5):2062-2069.

241. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, **Shyr Y**, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology* 2010;138(3):958-968.

242. Woodhams DC, Kenyon N, Bell SC, Alford RA, Chen S, Billheimer D, **Shyr Y**, Rollins-Smith LA. Adaptations of skin peptide defences and possible response to the amphibian chytrid fungus in populations of Australian green-eyed treefrogs, Litoria genimaculata. *Diversity and Distributions* 2010;16(4):703-712.

243. Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo Y, **Shyr Y**, Cortez D. Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. *Embo Reports* 2010;11(11):876-882. PMCID: PMC2966956.

244. Zheng W, Wen W, Gao YT, **Shyr Y**, Zheng Y, Long J, Li G, Li C, Gu K, Cai Q, Shu XO, Lu W. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. *Journal of the National Cancer Institute* 2010;102(13):972-981. PMCID: PMC2897876.

245. Biswas S, Nyman JS, Alvarez J, Chakravarthi A, Ayers A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, **Shyr Y**, Matrisian LM, Mundy GR. Anti-transforming growth factor β antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. *PLoS One* 2011;6(11). PMCID: PMC3214031.

246. Borkon MJ, Morrow SE, Koehler EA, **Shyr Y**, Hilmes MA, Miller RS, Neblett WW, Lovvorn HN. Operative Intervention for Complete Pancreatic Transection in Children Sustaining Blunt Abdominal Trauma: Revisiting an Organ Salvage Technique. *American Surgeon* 2011;77(5):612-620.

247. Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, **Shyr Y**, Wu JY, Chen J. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. *Cancer Research* 2011;71(3):976-987. PMCID: PMC3032824.

248. Dexheimer JW, Talbot TR III, Ye F, **Shyr Y**, Jones I, Gregg WM, Aronsky D. A computerized pneumococcal vaccination reminder system in the adult emergency department. *Vaccine* 2011;29:7035-7041. PMCID: PMC3168965.

249. Fohn LE, Rodriguez A, Kelley MC, Ye F, **Shyr Y**, Stricklin G, Robbins JB. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. *Journal of the American Academy of Dermatology* 2011;64(2):336-345.

250. Fox E, Miller T, Balko J, Kuba MG, Sanchez V, Smith A, Liu S, Gonzalez-Angulo A, Mills G, Ye F, **Shyr Y**, Manning HC, Buck E, Arteaga C. A kinome-wide screen identifies the Insulin/IGF1 receptor pathway as a mechanism of escape from hormone dependence in breast cancer. *Cancer Research* 2011;71(21):6773-6784. PMCID: PMC3206206.

251. Fu Z, Shrubsole MJ, Smalley WE, Wu H, Chen Z, **Shyr Y**, Ness RM, Zheng W. Association of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps by histologic type. *Cancer Prevention Research* 2011;4(10):1686-1697. PMCID: PMC3188364.

252. Funatogawa T, Funatogawa I, **Shyr Y**. Analysis of covariance with pre-treatment measurements in randomized trials under the cases that covariances and post-treatment variances differ between groups. *Biometrical Journal* 2011;53(3):512-524.

253. Horn L, Zhao Z, Sandler A, Johnson D, **Shyr Y**, Wolff S, Devore RF, Laskin J. A Phase II Study of Carboplatin and Irinotecan in Extensive Stage Small-Cell Lung Cancer. *Clinical Lung Cancer* 2011;12(3):161-165.

254. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, **Shyr Y**, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation* 2011;121(7):2750-2767. PMCID: PMC3127435.

255. Li M, Chen S, Zhang J, Chen H, **Shyr Y**. Wave-spec: a preprocessing package for mass spectrometry data. *Bioinformatics* 2011;27(5):739-740. PMCID: PMC3105479.

256. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, **Shyr Y**, Arteaga CL. A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. *Clinical Cancer Research* 2011;17(7):2024-2034. PMCID: PMC3221728.

257. Miller TW, Fox E, Balko JM, Ghazoui A, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Sánchez V, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Ye F, Miller WR, **Shyr Y**, Arteaga C. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. *Cancer Discovery* 2011;1(4):338-351. PMCID: PMC3204388.

258. Murff HJ, Shrubsole MJ, Chen Z, Smalley WE, **Shyr Y**, Ness RM, Zheng W. Non-steroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps. *Cancer Prevention Research* 2011;4(11):1799-1807. PMCID: PMC3203989.

259. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, **Shyr Y**, Moses HL. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. *Cancer Discovery* 2011;1(5):430-441. PMCID: PMC3297196.

260. Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, Manier ML, Olson SJ, Shah RN, Miller AN, Putnam JB, Miller YE, Franklin WA, Blot WJ, Carbone DP, **Shyr Y**, Caprioli RM, Massion PP. Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions. *Cancer Research* 2011;71(8):3009-3017. PMCID: PMC3110721.

261. Rosenbluth JM, Mays DJ, Jiang A, **Shyr Y**, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America* 2011;108(5):2076-2081. PMCID: PMC3033306.

262. **Shyr Y**. Rigorous quantitative sciences integration — the foundation of the drug approval in the personal genome era. *International Review of Thrombosis* 2011;6(1):36-43.

263. **Shyr Y**, Su P. Statistics in medical research. *Science Development* 2011;463(7):6-11.

264. Su PF, Chi YC, Li CI, **Shyr Y**, Liao YD. Analyzing survival curves at a fixed point in time for paired and clustered right-censored data. *Computational Statistics & Data Analysis* 2011;55(4):1617-1628.

265. Villegas R, Xiang YB, Elasy T, Li HL, Yang G, Cai H, Ye F, Gao YT, **Shyr Y**, Zheng W, Shu XO. Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. *American Journal of Clinical Nutrition* 2011;94(2):543-551. PMCID: PMC3142729.

266. White RL, Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, **Shyr Y**, Berry L, Zhao Z, Soong SJ, Leong SP. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. *Annals of Surgical Oncology* 2011;18(13):3593-3600. PMCID: PMC3461951.

267. Xing X, Li Q, Sun H, Fu X, Zhan F, Huang X, Li J, Chen C, **Shyr Y**, Zeng R, Li Y, Lu X. The discovery of novel protein-coding features in mouse genome based on mass spectrometry data. *Genomics* 2011;98(5):343-351.

268. Abramson RG, Su PF, **Shyr Y**. Quantitative metrics in clinical radiology reporting: a snapshot perspective from a single mixed academic-community practice. *Magnetic Resonance Imaging* 2012;30(9):1357-1366. PMCID:PMC3466403.

269. Baumann JL, Li M, Poulsen A, Chadwick NS, Cai Q, Chung CH, **Shyr Y**, Olsen JH, Zheng W, Slebos RJ. Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. *Cancer Epidemiology* 2012;36(1):e33-9. PMCID:PMC3259162.

270. Brantley-Sieders DM, Fan KH, Deming-Halverson SL, **Shyr Y**, Cook RS. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. *PLoS One* 2012;7(9):e45238. PMCID:PMC3460936.

271. Chen X, Li J, Gray W, Lehmann B, Bauer J, **Shyr Y**, Pietenpol, J. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. *Cancer Informatics* 2012;11:147-156. PMCID:PMC3412597.

272. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, **Shyr Y**, Yoder SM, Rock MT, Crowe JE Jr. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. *Experimental Hematology* 2012;40(12):974-982. PMCID: PMC3611587.

273. Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Chen Z, **Shyr Y**, Cai Q, Ness RM, Zheng W. Using gene-environment interaction analyses to clarify the role of well-done meat and heterocyclic amine exposure in the etiology of colorectal polyps. *American Journal of Clinical Nutrition* 2012;96(5):1119-1128. PMCID: PMC3471199.

274. Fu Z, Shurbsole MJ, Smalley WE, Wu H, Chen Z, **Shyr Y**, Ness RM, Zheng W. Lifestyle factors and their combined impact on the risk of colorectal polyps. *American Journal of Epidemiology* 2012;176(9):766-776. PMCID: PMC3571253.

275. Guo Y, Cai Q, Samuels DC, Ye F, Long J, Li C, Winther JF, Tawn EJ, Stovall M, Lähteenmäki P, Malia N, Levy S, Shaffer C, **Shyr Y**, Shu X, Boice JD Jr. The use of next generation sequencing technology to study the effect of radiation therapy on mitochondrial DNA mutation. *Mutation Research – Genetic Toxicology and Environmental Mutagenesis* 2012;744(2):154-160. PMCID:PMC3354959.

276. Guo Y, Li J, Li CI, Long J, Samuels DC, **Shyr Y**. The effect of strand bias in Illumina short-read sequencing data. *BMC Genomics* 2012;13(1):666. PMCID: PMC3532123.

277. Hong J, Katsha A, Lu P, **Shyr Y**, Belkhiri A, El-Rifai W. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. *Cancer Research* 2012;72(17):4504-4514. PMCID:PMC3432752.

278. Huang Y, Zhao Z, Xu H, **Shyr Y**, Zhang B. Advances in systems biology: computational algorithms and applications. *BMC Systems Biology* 2012;6 Suppl 3:S1. PMCID: PMC3524016.

279. Kikuchi T, Hassanein M, Amann JM, Liu Q, Slebos RJ, Rahman SM, Kaufman JM, Zhang X, Hoeksema MD, Harris BK, Li M, **Shyr Y**, Gonzalez AL, Zimmerman LJ, Liebler DC, Massion PP, Carbone DP. In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers. *Molecular & Cellular Proteomics* 2012;11(10):916-932. PMCID: PMC3494148.

280. Li X, Sterling JA, Fan K, Vessella RL, **Shyr Y**, Hayward SW, Matrisian LM, Bhowmick NA. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. *Molecular Cancer Research* 2012;10(4):494-503. PMCID: PMC3900026.

281. Liu Q, Guo Y, Li J, Long J, Zhang B, **Shyr Y**. Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. *BMC Genomics* 2012;13 Suppl 8:S8. PMCID: PMC3535703.

282. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, Jett JR, Putnam JB, Callaway-Lane C, Deppen S, Grogan EL, Carbone DP, Worrell JA, Moons KGM, **Shyr Y**, Massion PP. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. *Cancer Epidemiology, Biomarkers & Prevention* 2012;21(5):786-792. PMCID: PMC3660018.

283. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, **Shyr Y**, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* 2012;149(1):146-158. PMCID: PMC3563328.

284. Rao M, Song W, Jiang A, **Shyr Y**, Lev S, Greenstein D, Brantley-Sieders D, Chen J. VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. *PLoS One* 2012;7(10):e46281. PMCID:PMC3462209.

285. **Shyr Y**. Rigorous quantitative sciences integration: the foundation of high-dimensional genomic research. *Clin Exp Metastasis* 2012;29(7):641-643. PMCID:PMC3485411.

286. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JA, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, **Shyr Y**, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New England Journal of Medicine* 2012;366(8):707-714. PMCID: PMC3724515.

287. Stover DG, Reddy VK, **Shyr Y**, Savani BN, Reddy N. Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. *Bone Marrow Transplant* 2012;47(1):82-87.

288. Su PF, Chen X, Chen H, **Shyr Y**. Statistical aspects of omics data analysis using the random compound covariate. *BMC Systems Biology* 2012;6 Suppl 3:S11. PMCID: PMC3524312.

289. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik-Delmaire T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, **Shyr Y**, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 inhibits the growth of advanced human melanoma tumors. *Clinical Cancer Research* 2012;18(8):2184-2198. PMCID: PMC3724517.

290. Talati M, Seeley E, Ihida-Stansbury K, Delisser H, McDonald H, Ye F, Zhang X, **Shyr Y**, Caprioli R, Meyrick B. Altered expression of nuclear and cytoplasmic histone H1 in pulmonary artery and pulmonary artery smooth muscle cells in patients with IPAH. *Pulmonary Circulation* 2012;2(3):340-351. PMCID: PMC3487302.

291. Vlacich G, Diaz R, Thorpe SW, Murphy BA, Kirby W, Sinard RJ, Shakhtour B, **Shyr Y**, Murphy P, Netterville JL, Yarbrough WG, Cmelak AJ. Intensity-modulated radiation therapy with concurrent Carboplatin and Paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. *Oncologist* 2012;17(5):673-681. PMCID: PMC3360907.

292. Wentz SC, Zhao ZG, **Shyr Y**, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. *World Journal of Gastrointestinal Oncology* 2012;4(10):207-215. PMCID: PMC3581835.

293. Winther JF, Olsen JH, Wu H, **Shyr Y**, Mulvihill JJ, Stovall M, Nielsen A, Schmiegelow M, Boice JD Jr. Genetic disease in the children of Danish survivors of childhood and adolescent cancer. *Journal of Clinical Oncology* 2012;30(1):27-33. PMCID: PMC3255559.

294. Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, **Shyr Y**, Weaver KD, Thompson RC. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. *International Journal of Oncology* 2012;40(6):1995-2003.

295. Ye F, Bauer JA, Pietenpol JA, **Shyr Y**. Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives. *BMC Genomics* 2012;13 Suppl 8:S3. PMCID: PMC3535706.

296. Ye F, **Shyr Y**. Adaptive clinical trial design: From simple dose-finding trials to large-scale personalized medicine trials. *Personalized Medicine Oncology* 2012;1(4).

297. Zhao Z, Huang Y, Zhang B, **Shyr Y**, Xu H. Genomics in 2012: challenges and opportunities in the next generation sequencing era. *BMC Genomics* 2012;13 Suppl 8:S1. PMCID: PMC3535713.

298. Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, **Shyr Y**, Lin L, Carbone DP, Brantley-Sieders DM, Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. *Journal of the National Cancer Institute* 2012;104(15):1183-1198. PMCID: PMC3611812.

299. Al-Greene NT, Means AL, Lu P, Jiang A, Schmidt CR, Chakravarthy AB, Merchant NB, Washington MK, Zhang B, Shyr Y, Deane NG, Beauchamp RD. Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. *PLoS One* 2013;8(7):e69660. PMCID:PMC3726759.

300. Ausborn NL, Wang T, Wentz SC, Washington MK, Merchant NB, Zhao Z, **Shyr Y**, Chakravarthy AB, Xia F. 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. *BMC Cancer* 2013;13(1):155. PMCID: PMC3636043.

301. Dexheimer JW, Abramo TJ, Arnold DH, Johnson KB, **Shyr Y**, Ye F, Fan KH, Patel N, Aronsky D. An asthma management system in a pediatric emergency department. *International Journal of Medical Informatics* 2013;82(4):230-238. PMCID: PMC3646328.

302. Guo Y, Li J, Li CI, **Shyr Y**, Samuels DC. MitoSeek: Extracting mitochondrial information and performing high throughput mitochondria sequencing analysis. *Bioinformatics* 2013;29(9):1210-1211.

303. Guo Y, Li CI, Sheng Q, Winther JF, Cai Q, Boice JD, **Shyr Y**. Very low-level heteroplasmy mtDNA variations are inherited in humans. *Journal of Genetics and Genomics* 2013;40(12):607-615.

304. Guo Y, Li CI, Ye F, **Shyr Y**. Evaluation of read count based RNAseq analysis methods. *BMC Genomics* 2013;14(Suppl 8):S2. PMCID: PMC Journal – In progress.

305. Guo Y, Samuels DC, Li J, Clark T, Li CI, **Shyr Y**. Evaluation of allele frequency estimation using pooled sequencing data simulation. *ScientificWorldJournal* 2013;2013:895496. PMCID: PMC3582166.

306. Guo Y, Sheng Q, Li J, Ye F, Samuels DC, **Shyr Y**. Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. *PLoS One* 2013;8(8):e71462. PMCID: PMC3748065.

307. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, Pietenpol J, Shyr Y. Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. *BioMed Research International* 2013;2013:915636. PMCID: PMC3835197.

308. Hansen AG, Freeman TJ, Arnold SA, Starchenko A, Jones-Paris CR, Gilger MA, Washington MK, Fan KH, **Shyr Y**, Beauchamp RD, Zijlstra A. Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome. *Cancer Research* 2013;73(10):2955-2964. PMCID: PMC3660148.

309. Han D, Zager JS, **Shyr Y**, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. *Journal of Clinical Pathology* 2013;31(35):4387-4393.

310. Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, Tantawy MN, Manning HC, Lu P, **Shyr Y**, Ecsedy J, Belkhiri A, El-Rifai W. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. *Gastroenterology* 2013;145(6):1312-1322. PMCID: PMC3840093.

311. Li C-I, Su P-F, Guo Y, **Shyr Y**. Sample size calculation for differential expression analysis of RNA-seq data under Poisson distribution. *International Journal of Computation Biology and Drug Design* 2013;6(4):358-375. PMCID: PMC3874726.

312. Li C-I, Su P-F, **Shyr Y**. Sample size calculation based on exact test for assessing differential expression analysis in RNA-seq data. *BMC Bioinformatics* 2013;14(1):357.

313. Liu Q, Halvey PJ, **Shyr Y**, Slebos RJ, Liebler DC, Zhang B. Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation. *Mol Cell Proteomics* 2013;12(7):1900-1911. PMCID: PMC3708174.

314. Lu X, An H, Jin R, Zou M, Guo Y, Su PF, Liu D, **Shyr Y**, Yarbrough WG. PPM1A is a RelA phosphatase with tumor suppressor-like activity. *Oncogene* 2013. PMCID: PMC3897569.

315. Mikhitarian K, Pollen M, Zhao Z, **Shyr Y**, Merchant NB, Parikh A, Revetta F, Washington MK, Vnencak-Jones C, Shi C. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. *Modern Pathology* 2013.

316. Qiu Q, Lu P, Xiang Y, **Shyr Y**, Chen X, Lehmann BD, Viox DJ, George AL Jr, Yi Y. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. *PLoS One* 2013;8(1):e54979. PMCID: PMC3558433.

317. Rexer BN, **Shyr Y**, Arteaga CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. *Journal of Clinical Oncology* 2013;31(17):2073-2075.

318. Samuels DC, Han L, Li J, Quanghu S, Clark TA, **Shyr Y**, Guo Y. Finding the lost treasures in exome sequencing data. *Trends Genet* 2013;29(10):593-599.

319. Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, **Shyr Y**, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. *BMC Systems Biology* 2013;7(Suppl 5):S1. PMCID: PMC Journal – In progress.

320. Wang T, Wentz SC, Ausborn NL, Washington MK, Merchant N, Zhao Z, **Shyr Y**, Chakravarthy AB, Xia F. Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. *Pancreas* 2013;42(6):977-982.

321. Yan L, Womack B, Wotton D, Guo Y, **Shyr Y**, Dave U, Li C, Hiebert S, Brandt S, Hamid R. Tgif1 regulates quiescence and self-renewal of hematopoietic stem cells. *Molecular and Cell Biology* 2013;33(24):4824-4833. PMCID: PMC3889555.

322. Abrams JA, Appelman HD, Beer DG, Berry LD, Chak A, Falk GW, Fitzgerald RC, Ginsberg GG, Grady WM, Joshi BP, Lynch JP, Markowitz S, Richmond E, Rustgi AK, Seibel EJ, Shaheen NJ, **Shyr Y**, Umar A, Wang KK, Wang TC, Wang TD, Yassin R. Barrett's Esophagus Translational Research Network (BETRNet): The pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. *Gastroenterology* 2014.

323. Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, Lafrance DR, Vnencak-Jones CL, **Shyr Y**, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. *Breast Cancer Res Treat* 2014.

324. Cardin DB, Goff L, Li CI, **Shyr Y**, Winkler C, Devore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. *Cancer Med* 2014.

325. Cleveland SM, Goodings C, Tripathi RM, Elliott N, Thompson MA, Guo Y, **Shyr Y**, Dave UP. LIM domain only-2 (Lmo2) induces T-cell leukemia with epigenetic deregulation of CD4. *Exp Hematol* 2014.

326. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, Pietenpol J, Samuels DC, **Shyr Y**. Multi-perspective quality control of Illumina exome sequencing data using QC3. *Genomics* 2014.

327. Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, **Shyr Y**, Moses HL, Hayward SW, Sterling JA, Zijlstra A. ALCAM/CD166 is a TGF-beta responsive marker and functional regulator of prostate cancer metastasis to bone. *Cancer Research* 2014.

328. Lammers PE, **Shyr Y**, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. *J Thorac Oncol* 2014;9(4):559-562.

329. Shen EZ, Song CQ, Lin Y, Zhang WH, Su PF, Liu WY, Zhang P, Xu J, Zhan C, Wang X, **Shyr Y**, Cheng H, Dong MQ. Mitoflash frequency in early adulthood predicts lifespan in *Caenorhabditis elegans*. *Nature* 2014.

330. Sidorova T, Mace LC, Wells KS, Yermalitskaya LV, Su PF, **Shyr Y**, Byrne JG, Petracek, MR, Greelish, JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Quantitative imaging of preamyloid oligomers, a novel structural abnormality in human atrial samples. *J Histochem Cytochem* 2014.

331. Strother MK, Anderson MD, Singer RJ, Du L, Moore RD, **Shyr Y**, Ladner TR, Arteaga D, Day MA, Clemmons PF, Donahue MJ. Cerebrovascular collaterals correlate with disease severity in adult North American patients with Moyamoya disease. *AJNR Am J Neuroradiol* 2014.

332. Su PF, Li CI, **Shyr Y**. Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. *Computational Statistics and Data Analysis* 2014;74:39-51. PMCID: PMC3931470.

333. Vlacich G, Spratt DE, Diaz R, Phillips JG, Crass J, Li CI, **Shyr Y**, Cmelak AJ. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. *Radiother Oncol* 2014.

334. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, **Shyr Y**, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL Jr, Roden DM. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. *J Am Coll Cardiol* 2014;63(14):1430-1437.

PAPERS DELIVERED AT PROFESSIONAL MEETINGS AND ABSTRACTS — MORE THAN 200

APPEARS THIS WAY ON ORIGINAL.